Cobalt toxicity in humans : a review of the potential sources and systemic health effects

Title: Cobalt toxicity in humans. A review of the potential sources and systemic health effects.

Authors: Laura Leyssens, Bart Vinck, Catherine Van Der Straeten, Floris Wuyts, Leen Maes

PII: S0300-483X(17)30155-5
DOI: http://dx.doi.org/doi:10.1016/j.tox.2017.05.015
Reference: TOX 51888

To appear in: *Toxicology*

Received date: 30-3-2017
Revised date: 17-5-2017
Accepted date: 24-5-2017

Please cite this article as: Leyssens, Laura, Vinck, Bart, Van Der Straeten, Catherine, Wuyts, Floris, Maes, Leen, Cobalt toxicity in humans.A review of the potential sources and systemic health effects.Toxicology http://dx.doi.org/10.1016/j.tox.2017.05.015

Cobalt toxicity in humans. A review of the potential sources and systemic health effects.

Laura Leyssens[a], Bart Vinck[a,b], Catherine Van Der Straeten[c,d], Floris Wuyts[e,f], Leen Maes[a,g].

[a] *Faculty of Medicine and Health Sciences, University of Ghent (Belgium)*
Department of Speech, Language and Hearing Sciences
University Hospital Ghent, policlinic 1 floor 2
De Pintelaan 185
9000 Ghent
Belgium
Laura.Leyssens@UGent.be ***(corresponding author)***
LeenK.Maes@UGent.be

[b] *Faculty of Humanities, University of Pretoria (South Africa)*
Department of Speech-Language Pathology and Audiology
Aula Theatre, University Road
Pretoria, 0001
South Africa
Bart.Vinck@up.ac.za

[c] *Faculty of Medicine, Imperial College London*
Department of Surgery & Cancer
Musculoskeletal Sciences and Technology
Imperial College London
Charing Cross Campus, 7L21 Lab Block
London SW7 2AZ
UK
c.van-der-straeten@imperial.ac.uk

[d] *Faculty of Medicine and Health Sciences, University of Ghent (Belgium)*
De Pintelaan 185
9000 Ghent
Belgium

[e] *Antwerp University Research center for Equilibrium and Aerospace (AUREA)*
Department of Otorhinolaryngology
University Hospital Antwerp
Campus Groenenborger
Groenenborgerlaan 171
2020 Antwerp
Belgium
Floris.Wuyts@uantwerpen.be

[f] *Department of Biomedical Physics, University of Antwerp (Belgium)*
Campus Groenenborger
Groenenborgerlaan 171
2020 Antwerp
Belgium

[g] *Clinical audiology department*
University Hospital Ghent
De Pintelaan 185
9000 Ghent
Belgium

Abstract

Cobalt (Co) and its compounds are widely distributed in nature and are part of numerous anthropogenic activities. Although cobalt has a biologically necessary role as metal constituent of vitamin B_{12}, excessive exposure has been shown to induce various adverse health effects. This review provides an extended overview of the possible Co sources and related intake routes, the detection and quantification methods for Co intake and the interpretation thereof, and the reported health effects. The Co sources were allocated to four exposure settings: occupational, environmental, dietary and medical exposure. Oral intake of Co supplements and internal exposure through metal-on-metal (MoM) hip implants deliver the highest systemic Co concentrations. The systemic health effects are characterized by a complex clinical syndrome, mainly including neurological (e.g. hearing and visual impairment), cardiovascular and endocrine deficits. Recently, a biokinetic model has been proposed to characterize the dose-response relationship and effects of chronic exposure. According to the model, health effects are unlikely to occur at blood Co concentrations under 300 µg/l (100 µg/l respecting a safety factor of 3) in healthy individuals, hematological and endocrine dysfunctions are the primary health endpoints, and chronic exposure to acceptable doses is not expected to pose considerable health hazards. However, toxic reactions at lower doses have been described in several cases of malfunctioning MoM hip implants, which may be explained by certain underlying pathologies that increase the individual susceptibility for Co-induced systemic toxicity. This may be associated with a decrease in Co bound to serum proteins and an increase in free ionic Co^{2+}. As the latter is believed to be the primary toxic form, monitoring of the free fraction of Co^{2+} might be advisable for future risk assessment. Furthermore, future research should focus on longitudinal studies in the clinical setting of MoM hip implant patients to further elucidate the dose-response discrepancies.

Keywords: cobalt; systemic cobalt toxicity; medical cobalt exposure; dietary cobalt exposure; occupational cobalt exposure; metal-on-metal hip implants

1. Introduction

Cobalt (Co) is a hard, silvery gray and ductile metal element, of which the chemical properties are highly similar to iron (Fe) and nickel (Ni) [1]. Cobalt compounds predominantly occur in two valence states: cobaltous (Co^{2+}) and cobaltic (Co^{3+}), the former being most commercially and environmentally available [1, 2]. Furthermore, cobalt metal ions are trace elements widely distributed in nature. Trace elements are - in specific quantities - essential for normal physiological function; they play a role in the prevention of nutritional deficiencies, the functioning of the immune system, the regulation of gene expression, the antioxidant defense and the prevention of chronic diseases [3]. The only known biological function of cobalt is its role as metal component of vitamin B_{12}, also named cyanocobalamin [3, 4], whereas other cobalt compounds have been described as toxic for the environment and the human body following excessive exposure.

Because of its widespread occurrence, humans are frequently exposed to various Co compounds in daily life. The general population is primarily exposed through inhalation of ambient air and ingestion of food and drinking water containing Co compounds [4]. Occupational exposure to cobalt is another relatively frequent event, as cobalt has numerous industrial applications (production of hard metals, grinding, mining, paint) [1, 4]. Furthermore, cobalt is or has been used for a number of medical purposes, some of which were abandoned over the years [1, 4, 5].

The toxic potential of cobalt and the related health risks have been investigated thoroughly in animal and human toxicity studies. Previous reviews often focused on either one specific exposure setting and the related Co intake routes, toxicity mechanisms and clinical consequences [6-16], or the effect of Co on a specific physiological system in different Co exposure settings [17-23]. A recent extensive review of Paustenbach et al. [2] covered the main cobalt sources, intake routes, kinetics, underlying toxicity mechanisms and a critical evaluation of

previously reported adverse health effects. Since their work already provides a comprehensive and detailed quantitative exposure and risk assessment [2, 24-26], our goal was to provide a more general and concise overview of the following areas:

(1) The historical and contemporary cobalt sources in different exposure settings, with the related intake routes.

(2) The instruments for detection and quantification of Co intake, and the recent insights regarding the interpretation of these measures.

(3) The currently known systemic human health effects.

2. Cobalt sources

For thousands of years, cobalt has been used as a coloring agent for glass, pottery and jewelry because of the characteristic blue color of certain compounds [27]. Cobalt was isolated and identified as an element in the eighteenth century, and its use in industrial applications commenced in the beginning of the twentieth century [1]. An extensive array of historical and contemporary Co sources is documented in the literature. In this review, four exposure categories were distinguished to group the different sources: (1) occupational, (2) environmental, (3) dietary and (4) medical exposure.

2.1. Occupational exposure

2.1.1. Hard metal industry

With almost 15% of the worldwide production of Co being used for hard metal production [28], the hard metal industry is believed to represent the main source of occupational Co exposure. Cobalt (Co), tungsten (W) and tungsten carbides (WC) are the major constituents of hard metal alloys, and thus commonly used in the production and processing of hard metals. Tungsten carbide (WC) is the key component of the alloy mixture ($\geq$ 90%), whereas Co is less represented ($\leq$ 10%) and used as a binder [29]. The combination of Co with WC is assumed to enhance the cellular uptake of Co and modulate its biological reactivity and toxic effect [1, 30, 31]. Cobalt uptake in the hard metal industry mainly results from inhalation of hard metal dust, although dermal uptake has also been demonstrated [32]. When only considering the inhalation pathway, the uptake is determined by the airborne workplace concentration, the duration of the working shift, the breathing volume per minute, and the percent retention of dust in the airways. Furthermore, smoking has been shown to increase the Co intake via the dust-hand cigarette-mouth path [33]. The airborne workplace concentration typically differs between departments within a hard metal plant. For cobalt, the highest levels were measured in the powder production areas, the

sintering workshop and the pressing department [34-37]. Overall, the airborne workplace levels of Co and tungsten dusts have significantly decreased over the years [33], which has been associated with improved hygiene and protection measures [38]. This decrease can be illustrated by two recent studies: Hutter et al. [33] reported airborne Co levels ranging between 0.001 and 8 mg/m^3 measured between 1985 and 2012 in a large Austrian hard metal plant, whereas much lower levels were found by Klasson et al. [28] between 2007 and 2009 in a Swedish hard metal plant (range: 0.000028-0.056 mg/m^3). This trend is seen in many other industries as well [39-42], and the currently measured levels are mostly well below the occupational exposure limit (OEL) as stipulated by different (inter)national institutions for occupational health (e.g. American Conference of Governmental Industrial Hygienists (ACGIH): 0.02 mg/m^3; Austrian Occupational Safety and Health Administration (OSHA): 0.1 mg/m^3; National Institute for Occupational Safety and Health (NIOSH): 0.05 mg/m^3; Swedish Work Environment Authority (SWEA): 0.02 mg/m^3) [28, 33].

2.1.2. Construction industry

Cobalt exposure may also occur in the construction industry, primarily through skin contact with cement. Irritant and allergic contact dermatitis are considered the most frequent occupational health hazards in cement workers [43]. Morrone et al. [44] studied the clinical-epidemiological features of contact dermatitis in rural and urban areas in Northern Ethiopia. They found a strong positive correlation between the reactivity to cobalt chloride and being a construction worker. However, reactivity to Co alone is rare and is mostly associated with reactivity to chromate [45], which was confirmed by their findings. Chromate was found to be the most common contact allergen among construction workers, followed by epoxy resin and cobalt [43, 46-48]. According to the authors, this finding indicates that the concomitant hypersensitivity to cobalt and chromate is the result of an actual simultaneous sensitization due to combined exposure, rather than a cross-reaction between both allergens [44].

2.1.3. E-waste recycling industry

Several electric and electronic devices have been reported to contain and release cobalt, often with concentrations far above the local legal threshold [49-51]. Consequently, employees in the e-waste recycling industry might be significantly exposed to cobalt. Three main exposure routes were described by Grant, Goldizen [52] in this context: inhalation, skin contact and oral ingestion. The exposure rate is assumed to be variable, depending on whether formal or informal recycling techniques are implemented. In formal recycling factories (typically in Europe and North America), the workers are mostly properly protected and the equipment is specifically designed for the recycling of e-waste [53]. In Africa, Asia and South America, more informal recycling factories are seen, where techniques such as cutting, acid bathing and open burning are used and the workers may not be protected at all [54]. A Swedish study of Julander et al. [55] characterized the metal exposure in workers performing formal recycling of e-waste compared to office workers. Regarding Co specifically, they observed a 15 times greater airborne exposure and significantly higher blood and urine concentrations in the recycling workers versus office workers. A similar study performed in e-waste recycling factories in Ghana [56] revealed much higher exposure values to several metals, which may be attributed to the application of informal recycling methods.

2.1.4. Diamond industry

Diamond polishers often use high-speed polishing disks of which the surface is composed of microdiamonds, cemented in ultrafine cobalt metal powder. During polishing activities, Co dust is formed and may be inhaled by the diamond polisher [1], which has been shown to cause respiratory impairment [57-63].

2.1.5. Pigment production and paint industry

Cobalt is often present in certain paints or inks as siccative to facilitate the drying process [64] and in cobalt blue dyes for painting porcelain pottery [14, 65]. Skin contact and inhalation of paint fumes/dusts are the primary exposure routes [14, 66, 67].

2.2. Environmental exposure

2.2.1. Contaminated air, water & soil

Different cobalt compounds are widely dispersed in nature, generally in low concentrations. Atmospheric Co levels at unpolluted sites are generally lower than 2.0 ng/m^3 [4, 68-72]. The earth's crust has an average Co concentration of 25 mg/kg [1], and the mean soil concentration in the US is 7.2 mg Co/kg (range 1-40 mg/kg) [73, 74]. Cobalt is rarely detected in drinking water, and if so, the concentration is low (range 0.1-5 µg/l) [75]. In lakes, rivers and groundwater Co may be present in trace amounts [69], and in open ocean waters the average concentration is estimated around 0.3 µg/l [1].

Air, water and soil pollution by Co and other metal compounds typically occurs in areas near factories and in heavily industrialized cities [76]. Incineration of combustible municipal solid waste is a primary example of polluting activity. The remaining bottom ash contains heavy metals (including Co) that can leach into soil and groundwater, which may result in long-term risks to the environment [77]. Feng et al. [77] reported Co concentrations lower than 0.01 mg/l in the groundwater of such areas (called *leachates*), which is rather low in comparison with other heavy metals (e.g. zinc, lead). Also in the context of waste processing, the recycling of e-waste might contaminate the surrounding area. Lim et al. [51] developed a pathway and impact model for the heavy metals in e-waste, which may be distributed in flue gas, fly ash and bottom ash after incineration or leaching in water near landfills. Cobalt was primarily found in bottom ash (90%) and fly ash (10%) [78] and showed an ecotoxicity potential for water according to the model.

Furthermore, environmental pollution may be caused by mining activities. The Idaho Cobalt Belt (ICB) in the USA and the Katanga Copperbelt (KC) in Congo are enormous mining zones where Co concentrations in the surrounding rivers, air and soil are highly elevated above regional background levels (ICB[79]: 0.12 µg/l in water, 12 µg/g in soil ; KC[80]: <0.001 µg/l in drinking water, 20 µg/g in soil, 11 µg/g in indoor and outdoor dust) and limits posed by national agencies for environmental protection (e.g. United States Environmental Protection Agency, US EPA: target clean-up level of 80 µg/g and 86 µg/l for Co in sediment and surface water, respectively) [79-83]. A biomonitoring study of Banza et al. [84] in the KC revealed substantially increased urinary Co levels measured in people living nearby compared to control subjects. In recent work from the same group [80], the Co concentration in several environmental samples was determined and linked to biomonitoring data from people living in polluted areas and control areas. This analysis indicated that dietary Co intake (vegetables, cereals and fish) and ingestion of contaminated dust are the main human exposure routes in the polluted areas, of which the latter is especially significant in children.

2.2.2. Electronic devices

A small number of studies delivered evidence for Co release from several (depleted) electronic devices. For instance, depleted rechargeable batteries used in mobile phones were shown to contain Co levels exceeding the locally (California, USA) established toxicity threshold limit (8000 mg/kg) with a factor between 20 and 45 [49, 50]. Kang et al. [49] utilized hazard assessment models to estimate the toxicity potential of such batteries and revealed an association between cobalt (among other metals) and both ecotoxicity and human toxicity. Furthermore, Lim et al. [51] warned for the toxic potential of metals detected in new types of flat panel display (FPD) devices such as plasma TVs, LCD (liquid crystal display) TVs, LCD computer monitors and laptop computers. Compared to the other metals, Co was identified in rather small amounts and its derived toxicity potential was limited to 'ecotoxic in water'. At last, a few studies

demonstrated Co release from mobile phones [85-87]. Skin contact is assumed to be the main human intake pathway, but all abovementioned studies mainly focused on measuring the Co content and release from these devices.

2.2.3. Cosmetics & jewelry

Cosmetic products (eye pencil, eye shadow, lipstick, skin cream, soap, …) are widespread Co sources for humans with varying Co concentrations [12]. The use of Co and Co salts in cosmetics is forbidden by the EU regulation on cosmetics and intentional ingredients, but their presence is allowed as impurities when technically necessary [88, 89]. There are no fixed permissible levels for these impurities so far and forbidden metals may accidentally end up in the product, for example by use of plants and herbs contaminated with metals [90-92].

Several jewelry items may contain and release Co, but the Ni release and concentration in jewelry is much higher and Ni allergy is one of the most frequent causes of allergic contact dermatitis worldwide [93-98]. However, concomitant Ni and Co allergy is frequently seen, since cobalt is often mixed with or serves as impurity in other metals [21, 95]. Inexpensive dark-colored items were found to release more Co than the more expensive and lighter-colored variants [93, 97, 99].

The permeation process of Co through human skin is scarcely documented. In vitro experiments of Larese et al. [100] demonstrated that Co powders are oxidized into Co ions by sweat, resulting in permeation. This process appears to be easier for damaged skin than for intact skin [101], and metal nanoparticles penetrate the skin even better because of their very small size [102]. However, there are no in vivo data indicating that Co ions can permeate through the skin into the blood stream and internal organs. They were found to accumulate in the deeper layers of the *stratum corneum*, causing merely local skin reactions (i.e. allergic contact dermatitis) [101, 103-107]. However, some jewelry items (e.g. piercings) penetrate the epidermal barrier and may cause more profound trauma. Consequently, interaction between the metal

substrate and body fluids may lead to a corrosion action, causing a release of metal ions that bind to tissue and interstitial fluid proteins [97, 108].

2.2.4. Other

Recent research showed that leather goods can also contain cobalt and may subsequently cause Co allergy [109, 110]. Furthermore, Bjoernber [111] described allergic reactions due to the use of Co as a light blue tattoo pigment (azure blue and cobaltous aluminate).

2.3. Dietary exposure

For the general population, the diet is believed to be the main source of Co exposure [4, 112]. Hundreds of food items contain Co in varying concentrations [113]. The highest mean Co concentrations were found in chocolate, butter, coffee, fish, nuts, green leafy vegetables and fresh cereals [5, 114-118]. Vitamin B_{12} is mainly found in meat and dairy products [4]. Trace elements in food may originate from environmental sources (e.g. pollution from industrial or other anthropogenic activities) or from food processing and packaging [116]. In the past 10-15 years, several countries performed 'Total Diet Studies' (TDS); national surveys to assess public health risks associated with substances in food [116, 118-125]. These studies reported a mean dietary Co intake ranging from 0.13 to 0.48 µg/kg bw/day (bw=body weight) in adults and from 0.27 to 0.31 µg/kg bw/day in children, which is far below the lower limit of tolerable daily Co intake set by the Agence Française de Sécurité Sanitaire des Aliments (AFSSA) (1.6-8 µg/kg bw/day)[116].

In addition to the unintentional dietary Co intake, people may deliberately ingest cobalt in the form of Co-containing supplements or vitamin B_{12} supplements that are widely available for sale. The supplement manufacturers present Co as a contributor to protein synthesis, red blood cell production, fat and carbohydrate metabolism, and myelin sheath repair in the central nervous system [126-128]. The recommended daily intake of vitamin B_{12} for adults is 2.4 µg/d, which contains 0.1 µg of cobalt [129]. Furthermore, there are concerns about Co being misused as

blood doping agent by athletes to enhance aerobic performance [130, 131], and some energy drinks may contain high amounts of vitamin B_{12} [132].

The gastro-intestinal absorption of Co in humans was reported to be approximately 25% of the administered dose, but the inter-individual variation is considerably large (5-95%) due to its dependence of several factors: the ingested dose, the solubility of the compound and the nutritional status (e.g. iron deficiency) of the individual [1, 5, 112, 133-140]. There are no differences in gastro-intestinal absorption rates between the ionic forms of cobalt (Co^{2+} and Co^{3+}) [141]. The mechanism of gastro-intestinal Co absorption appears to occur from the proximal jejunum through a saturable process, and the intestinal Co uptake starts with mucous absorption followed by transfer from the enterocytes [141]. Furthermore, the Co gastro-intestinal absorption involves mechanisms common with Fe^{2+}, as people with iron deficiency show an increased Co absorption [139]. After absorption (from all intake routes), Co is mainly disseminated to the serum, whole blood, liver, kidneys, heart and spleen. Lower concentrations are observed in the skeleton, hair, lymphatic circulation, brain and pancreas [2, 112, 134, 142-149]. The kidneys are predominantly responsible for the excretion of absorbed cobalt [4, 116].

2.4. Medical exposure

2.4.1. Treatment of anemia

In the 1950s and 1960s, various Co preparations (e.g. cobaltous chloride or $CoCl_2$) were used in the treatment of anemia because of its stimulant effect on the hemoglobin and red blood cell production. The average daily doses (25 to 300 mg $CoCl_2$/day) were considerably high and often taken for several months [2, 150-153]. Due to frequent development of severe adverse health effects and a paucity of positive responses, this therapy is not applied anymore today [154].

2.4.2. Treatment of estrogen hyperexcretion

Menopausal or post-menopausal women often receive hormone replacement therapy. Occasionally, the therapy may fail to relieve the typical menopausal symptoms (e.g. hot

flashes). Compared to the women responding well to the treatment, these patients showed excessive excretion of estrogen, which was assumed to result from an overactivity of cytochrome enzymes. Since cobalt, among other minerals, can affect cytochrome function, Co supplements are sometimes prescribed to improve the therapeutic effect [155]. The administered doses (0.5 to 1.12 mg $CoCl_2$/day) are comparable with the averagely ingested dose of over-the-counter supplements [2, 155].

2.4.3. Metal-on-metal hip prostheses

Today, the population of metal-on-metal (MoM) hip implant patients is considered to undergo the most important Co exposure from non-dietary and non-occupational sources [25]. It was estimated that approximately 1.000.000 MoM articulations have been implanted worldwide since 1996 [156, 157]. Between 1990 and 2010, MoM implants represented approximately 10% of all hip arthroplasties in developed countries [158, 159].

Metal-on-metal hip prostheses are predominantly comprised of cobalt (64%) and chromium (Cr) (28%), but can contain small amounts (0.2-7%) of other metals (e.g. molybdenum, aluminum, nickel, manganese, iron, lanthanum) [160-162]. Currently, two types of hip replacements are performed with MoM implants: total hip arthroplasty (THA) or hip resurfacing arthroplasty (HRA). In the latter one, the patient's femur is preserved and capped with a metal component, allowing higher activity levels and better survivorship. Therefore, HRA is frequently executed in younger patients [163-165]. Cobalt and chromium ions may be formed and released as a result of two processes: friction between the articulating surfaces producing numerous nano-sized wear particles [166-168], and corrosion of the metal surfaces and wear particles [169-171]. Several factors may negatively influence this wear process and enhance the metal ion release or lead to higher metal ion levels: suboptimal surgical positioning of the implant [172, 173], mixing components from different manufacturers or different types [174], many

modular connections with friction and chemical corrosion at the taper/trunnion junction [175], impaired renal function and bilateral MoM hip replacement [164].

Chemical analysis of periprosthetic tissue samples and several *in vitro* studies revealed that nano-sized wear particles from MoM implants are mainly composed of insoluble oxidized Cr^{3+}, with practically no Co content [166, 171, 176-181]. This was confirmed by the findings of Madl et al. [182] for well-functioning hip prostheses, which also showed a low volumetric wear rate. For mal-positioned implants, however, the balance can be skewed to a higher volumetric wear rate and larger particle sizes containing higher Co levels [182]. After being released from the CoCr nanoparticles, the highly soluble Co^{2+} ions bind with synovial fluid proteins and adjacent tissue surfaces [183, 184], followed by dissemination into the peripheral blood [185].

3. Detection and quantification methods, and interpretation

3.1. Target organ level

Measuring Co levels at the target organ level is often applied in the occupational setting, where the skin and the respiratory system are the main target organs of Co toxicity. For cutaneous intake of Co, conventional skin patch tests are mostly used [44, 48, 186]. For determination of the inhaled Co concentration, analysis of the exhaled breath condensate (EBC) was proposed by Goldoni et al. [187] and Mutti et al. [188]. However, Broding et al. [31] observed that the EBC Co concentration was not significantly correlated to the airborne workplace concentration and concluded that the EBC Co concentration is not a reliable indicator for Co exposure in the workplace.

3.2. Systemic level

For measurement of the ion concentration at the systemic level, various matrices can be used, such as urine, whole blood and serum. Different analytical methods are available [112]; to determine the urinary Co concentration, sample chelation and/or acid digestion followed by graphite furnace atomic absorption spectrometry (GF-AAS) is typically applied, with detection limits ranging from 0.1 to 2.4 µg/l. These techniques can also be used for whole blood and serum analyses, with detection limits of 2 µg/l and 0.02 µg/l, respectively. Furthermore, inductive-coupled atomic emission spectrometry (ICP-AES) and inductive-coupled plasma mass spectrometry (ICP-MS) are widely available techniques since the 1990s, of which the latter exhibits lower detection limits compared to GF-AAS and allows simultaneous multi-element analysis. The results can be expressed in different units. For blood or serum, parts per billion (ppb), micrograms per liter (µg/l), nanograms per milliliter (ng/ml), nanomoles per liter (nmol/l) and micromoles per liter (µmol/l) are frequently used. The urinary concentration is

often expressed in micrograms per gram creatinine (µg/g creatinine), micrograms per liter (µg/l), and micrograms per millimole creatinine (µg/mmol creatinine).

The urinary Co concentration is most commonly used as a biomarker in occupational exposure assessment [17]. However, one should take into account that the urinary Co concentration shows a rapid increase in the first hours after cessation of the exposure, with a peak at 3 hours post-exposure [189]. Numerous studies determined the blood and urinary Co concentrations in occupationally exposed individuals, which are listed in ***Table 1***. The ACGIH established a Biological Exposure Index (BEI) of 15 µg/l of Co in urine and 1 µg/l in blood at the end of the workweek, corresponding with an atmospheric exposure level of 0.02 mg/m^3 (Threshold Limit Value – Time-Weighted Average (TLV-TWA) over 8 hours) [190].

In the medical exposure setting, which is currently dominated by MoM hip implants, whole blood and serum are the preferred matrices, since the ion concentrations in urine samples are more variable and depend on the hydration of the patient [191]. Mean serum and whole blood Co concentrations were shown to be relatively similar and well correlated [192, 193]. However, oral Co supplementation studies of Finley et al. [24] and Paustenbach et al. [194] showed considerably higher serum versus whole blood Co concentrations during dosing, which the authors attributed to a rate-limited uptake of Co in red blood cells (RBC). Additionally, the post-dosing clearance of Co from the serum appeared to be considerably faster compared to the RBC, and the serum Co levels were found to be more variable during dosing. The latter has been related to inter-individual variability in the gastro-intestinal Co uptake and differences in the time interval between Co ingestion and the blood sample collection. These differences in variability and elimination rate suggest that the whole blood concentration might be the most appropriate measure to estimate the long-term average Co exposure [185], whereas the serum concentration might give a better indication of the recent or recently changed Co exposure [38]. Furthermore,

there is no standard rate of conversion between the respective concentration values, so it was concluded that whole blood and serum levels should not be used interchangeably [192, 195].

Various studies have shown that the metal ion levels will first increase to a maximum during the 'running-in' phase of the MoM device, which takes approximately 9 to 12 months postoperatively. Subsequently, the ion concentration is expected to decrease to a steady-state, whereas in mal-functioning implants it may increase further [196-200]. Hence, after the 12-month running-in phase, the systemic Co and Cr concentration (in whole blood or serum) is recommended as a screening tool for the *in vivo* performance of MoM hip prostheses [201]. Several authors reported a distinct association of elevated metal ion concentrations with an increased degree of wear and corrosion [202-204] and with the occurrence of periprosthetic complications (e.g. loosening) [205-207]. The majority of patients with well-functioning MoM implants have Co concentrations ranging between 0.2 and 10 µg/l [185, 196, 202, 208-215]. Different organizations attempted to define threshold values for the identification of patients with adverse local tissue reactions that require clinical follow-up or intervention. The Medicines and Healthcare products Regulatory Agency recommended a 7 µg/l threshold [201], which demonstrated only a modest sensitivity (57%) and specificity (65%) [216]. Van Der Straeten et al. [217] proposed a 4 µg/l threshold for unilateral HRA (uHRA) and a 5 µg/l threshold for bilateral HRA (bHRA), resulting in a higher specificity (95% for uHRA and 93% for bHRA) but lower sensitivity (25% for uHRA and 43% for bHRA). Sidaginamale et al. [204] reported a high sensitivity (94%) and specificity (95%) of 4.5 µg/l as threshold value for the detection of abnormal wear. The Mayo Clinic stated that Co serum levels above 10 µg/l indicate significant implant wear, whereas values between 4 and 10 µg/l reflect good condition of the MoM device [218]. In summary, it is clear that metal ion levels should be interpreted carefully and serve as an adjunct to clinical and radiographic evaluations, for which different clinical algorithms have been proposed [157, 217, 219-221].

Additionally, (highly) elevated Co concentrations have been related to certain systemic manifestations of Co toxicity [2, 222]. Van Der Straeten et al. [206] collected questionnaires, validated to detect cobaltism in occupationally exposed individuals, in a MoM hip implant population. They found a significant correlation between increasing Co levels and the prevalence of several toxicity symptoms, and concluded that patients with repeated Co concentrations exceeding 20 µg/l are at risk for systemic toxicity. Likewise, a recent systematic review of the published cases of probable systemic Co toxicity from MoM hip arthroplasty reported a significant association between the Co concentration and a quantitative measure of overall symptom severity [15]. However, the measured Co levels covered an extensive range of 10-1085 µg/l. Approximately half of these cases showed Co levels above 100 µg/l, of which the majority had a fractured ceramic head before implantation of the MoM bearing. The higher Co concentrations in this subgroup probably result from abrasion of the metal surface by residual ceramic fragments [223]. Despite abovementioned evidence for systemic Co toxicity from MoM implants, there is a current lack of uniform criteria concerning blood Co concentrations to guide physicians in the detection and management of this condition.

To this purpose, efforts have been made to characterize the dose-response relationship for Co-induced systemic health effects by a group of researchers [2, 24-26, 185, 222, 224-227]. They developed a biokinetic model for cobalt [26, 227], based on a series of novel (human) oral dosing studies [24, 25, 224-226] and existing animal and human toxicology data (see Paustenbach et al. [2]). The model allows an estimation of the blood and tissue Co concentrations associated with various Co-related systemic health effects for MoM implant patients and consumers of inorganic Co supplements during and after exposure [25]. This takes into account the 'background' Co blood concentration of the general population, which was estimated at 0.3 µg/l (range 0.04-0.9 µg/l) as a result of normal dietary Co intake, with 95% of the population having a value lower than 0.6 µg/l [211, 212, 215, 228-230]. According to the model, systemic effects

are unlikely to occur at Co levels below 300 µg/l in healthy individuals, which was proposed as 'point of departure' (POD). Respecting a safety factor of 3 to account for inter-individual variability and long-term Co exposure, it might be useful to start monitoring implant patients from Co levels of 100 µg/l [2]. However, susceptible individuals might exhibit adverse health effects at lower Co concentrations. This susceptibility has been related to the partitioning of Co in the serum: the largest portion (90-95%) binds with albumin and approximately 8% occurs as free ionic Co^{2+} [231-234], which is considered the primary toxic form [38, 235]. Certain disease states (e.g. renal failure, iron deficiency, sepsis, malnutrition, alcoholism) or medication intake may reduce the Co-albumin binding and thus increase the amount of free Co^{2+} ions, ultimately leading to toxic manifestations at lower doses. Consequently, closer follow-up of this subgroup of patients might be necessary [2].

Apart from the dose, the effect of the duration of exposure was also considered in the (refined) biokinetic model [26], based on the complex inter-relationships of renal clearance mechanisms, storage of Co in RBC and abovementioned Co-albumin binding characteristics. These factors taken into account, implant patients with well-functioning MoM devices are not expected to be at risk for adverse health effects after 10 years of exposure with a steady-state blood Co concentration of 10 µg/l [25].

4. Systemic health effects

The toxic reactions to Co exposure primarily depend on its chemical form. In the occupational and environmental setting, people are predominantly exposed to Co metal particles. In the medical setting (e.g. MoM hip implants), exposure to Co (nano)particles as well as Co ions occurs [38, 236].

Particle-responses are immune-mediated and induce local adverse tissue reactions [236]. For example, inhalation of Co dust may cause adverse respiratory effects and the formation of Co nanoparticles in the wear process of MoM hip implants may lead to inflammatory fluid collections or osteolysis. These particle-responses can be subdivided into two categories. 'Metal reactivity' is a normal innate immunity response that manifests as a nonspecific foreign-body reaction to a large amount of metal debris. In contrast, 'metal allergy' is an adaptive immunity response to a small amount of metal debris that occurs in people with a genetic allergic predisposition and is typically associated with contact dermatitis [191]. The exact role of Co in these local reactions is difficult to characterize, since Co particles are often mixed with other substances (e.g. nickel, metallic carbides) [237].

Systemic toxic reactions may arise when Co ions enter the blood and lymphatic circulation and subsequently disseminate to different organs [38]. In vitro experiments demonstrated that ionized cobalt (Co^{2+}) is the primary toxic form for systemic toxicity [38, 235] and more specifically the unbound (free) Co^{2+} ions, which are more bioavailable than their albumin-bound counterparts to interact with various cellular receptors, ion channels and biomolecules [2]. Consequently, a shift in the distribution of free versus bound cobalt towards a larger portion of free Co^{2+} ions is expected to increase the risk for toxic effects. The possible molecular mechanisms of action of free Co^{2+} ions, extensively reviewed by Paustenbach et al. [2], include generation of reactive oxygen species (ROS) and lipid peroxidation, interruption of

the mitochondrial function, alteration of calcium (Ca) and iron (Fe) homeostasis, interactions with body feedback systems triggering erythropoiesis, interruption of thyroid iodine uptake, and induction of genotoxic effects and possible perturbation of DNA repair processes. Involvement of these mechanisms in the toxic response depends on the blood or tissue Co concentrations [2].

Systemic Co toxicity manifests as a clinical syndrome with a variable presentation of neurological, cardiovascular and endocrine symptoms, depending on the systemic Co levels (blood/urine). This interpretation was already proposed in the MoM implant world, where these systemic effects are summarized in the 'arthroprosthetic cobaltism' syndrome [238, 239]. According to a review of the available animal and human dose-response data for adverse health effects [222], supplemented by the abovementioned biokinetic model [227], the lowest blood Co concentrations (around 300 µg/l) are typically associated with reversible hematological and endocrine symptoms. In contrast, more severe effects (e.g. neurologic and cardiac symptoms) were only seen at higher Co levels (> 700 µg/l). Applying these observations on the published cases of 'arthroprosthetic cobaltism', reviewed by Gessner et al. [15], Cheung et al. [240] and Zywiel et al. [16], there are some contradictions. Zywiel et al. [16] concluded that neurological (72%), cardiovascular (55%) and endocrine (50%) effects are most commonly seen in this condition, of which the former two also occurred for Co levels much lower than 700 µg/l and in several cases even below 300 µg/l. However, the anecdotal case reports often lack detailed information to properly estimate the responsibility of Co or other patient-specific factors for the reported symptoms [2, 241, 242]. Consequently, no consensus has been achieved regarding the 'threshold' Co concentration for systemic health effects, which warrants the need for controlled clinical studies in the future.

Below, the effect of Co exposure on different organ systems is further specified. Additionally, a section was dedicated to the occurrence of psychological dysfunction in Co-

exposed individuals and to the concerns regarding the carcinogenic effect of Co, which to date has not been substantiated.

4.1. Cardiovascular system

The toxic potential of Co was first discovered in the 1960s when heavy beer drinkers presented with symptoms of cardiomyopathy, which was attributed to the use of cobalt chloride ($CoCl_2$) or cobalt sulfate ($CoSO_4$) as foam stabilizer in beer [243-246]. However, it is likely that the poor nutritional status of these subjects and the alcoholism itself were contributing factors for the cardiac effects [1, 247] and/or made the person more susceptible for systemic Co toxicity [2]. In addition, several cases of cardiomyopathy were reported in hard metal workers [22, 248-250] and patients with a MoM hip implant [223, 238, 242, 251-259]. In most of these cases, necropsy revealed severely elevated Co levels in the myocardial tissue. Accordingly, research of Horowitz [260] and Linna et al. [261] revealed an association between cumulative Co exposure and an altered diastole by use of Doppler echocardiography measurements, suggesting that Co accumulation in the myocardium may damage the myocardial function. Furthermore, echocardiography has shown a moderately to severely reduced left ventricular systolic function and left ventricular or atrial hypertrophy [223, 238, 242, 257]. Reversible electrocardiographic (ECG) changes, hypertension and a faster heart rate have been described [262, 263]. Two patients presented with paroxysmal atrial fibrillation [242, 252], and three fatal cases of Co-induced cardiomyopathy have been reported to date [253, 255, 257].

4.2. Peripheral & central nervous systems

Cobalt-related neurotoxicity may cause peripheral as well as central deficits. The latter presumably result from the ability of Co to cross the very restrictive blood-brain barrier and deposit in the brain [264, 265].

A variety of symptoms have been described, related to hearing and balance [23, 223, 238, 241, 251, 257, 266-270], vision [23, 238, 252, 266, 269-272], cognitive function [223, 238, 241, 273], and sensory and motor performance [23, 238, 252, 268, 270]. Moreover, these symptoms often coincide with polyneuropathy.

Hearing loss is always sensorineural, but the degree may be variable and is often progressive. Furthermore, the hearing impairment is mostly bilateral and more severe in the high frequencies, but this was not always mentioned properly. In addition, patients may complain about tinnitus and vertigo/dizziness, the latter sometimes accompanied by nausea and vomiting. Visual impairment may include optic nerve atrophy (mostly bilateral), reduced visual acuity, complete blindness, retinal dysfunction, poor color vision, blurred vision, and irregular cortical visual responses. A cognitive decline may be characterized by poor concentration, memory loss (e.g. names and places), impaired attention, disorientation, difficulties with registration of new information, and inefficiency. Regarding the sensory and motor performance, the following problems were mentioned: tremor, incoordination, headaches, motor axonopathy, muscle weakness, slower conduction of sensory stimuli, dyesthesia in the extremities, gait disturbances, numbness and paresthesia. After cessation of the exposure, most of the neurological symptoms gradually improved or resolved. Nevertheless, persistence of the auditory and visual dysfunctions was seen in some cases, despite a substantial decrease in the blood Co concentration.

4.3. Endocrine system

Autopsy of the previously mentioned beer drinkers often revealed thyroid changes, which could be associated with primary myocardial disease [274]. Roy et al. [274] could not find any abnormalities macroscopically, but some microscopical lesions were apparent: follicular distortion, cellular changes and colloid depletion. Furthermore, numerous human studies have reported endocrine effects (e.g. goiter development and reduced iodide uptake) in orally Co-treated subjects, with daily Co doses ranging between 0.5 and 10 mg/kg bw/day and the

treatment duration between 2 weeks and 10 months [275-282]. These effects mostly disappeared after cessation of the exposure [275, 279]. Additionally, chronic thyroiditis, disturbance of the thyroid hormone metabolism (mostly hypothyroidism) and a reduced thyroid volume have been described in Co-exposed individuals [23, 65, 223, 238, 252, 253, 255, 268, 270].

4.4. Hematological system

As cobalt has a known stimulant effect on the RBC production, exposure to Co compounds may increase the RBC count (polycythemia), hematocrit and hemoglobin levels [4]. These effects were reported in a study of Davis et al. [283], in which six healthy men received daily doses of 150 mg $CoCl_2$ up to 22 days. The RBC count normalized approximately two weeks after cessation of the exposure. In contrast, two other oral dosing studies did not find any hematological effects after ingestion of similar or higher doses [276, 284]. Similarly, several authors have investigated the occurrence of hematological effects in occupationally exposed individuals, but could not reveal any abnormalities of this kind [263, 285, 286]. Furthermore, one anecdotal case report of systemic Co toxicity from MoM hip arthroplasty described polycythemia in their patient [254].

4.5. Respiratory system

The association between occupational (hard) metal exposure and dysfunctions of the respiratory system was first made by Jobs et al. [287], based on changes in chest radiographs indicating pneumoconiosis, a term for occupational lung disease. Bech et al. [288] introduced the term ‘hard metal disease’, later adapted to ‘hard metal lung disease’, to describe the respiratory effects due to inhalation of Co-containing dusts. Roto [289] reported cases of asthma in a Finnish cobalt production plant, later referred to as ‘hard metal asthma’ by Kusaka et al. [34]. Information about the clinical and histopathological presentation of this disease is mainly based on case reports and small trials [34, 62, 288-296]. Currently, the scientific community recognizes three entities associated with the inhalation of hard metal dust: (1) occupational asthma, (2) allergic alveolitis

or hypersensitivity pneumonitis, and (3) interstitial pneumonia, presenting in two varieties: the typical giant cell pneumonia or the desquamative type without giant cells [294, 296]. Allergic alveolitis or hypersensitivity pneumonitis usually occurs in the acute stage of the exposure as an early inflammatory phase of fibrosis, but may evolve to a chronic fibrosis after long-term exposure [297-301]. Symptoms of giant cell interstitial pneumonia include weight loss, fatigue, dry cough, dyspnea on exertion, chest pain, wheezing and rales at the end of inhalation [301-303]. Cyanosis, digital clubbing, pulmonary hypertension, signs of right heart failure and cor pulmonale may arise when the disease progresses to fibrosis [301, 304]. Pulmonary dysfunction can be of the restrictive or obstructive type [299, 304], and pneumothorax has been observed in a limited number of cases [293, 296, 305, 306]. Progression of the disease after cessation of the exposure is a frequent finding [307]. Although Co is mostly incorporated in alloys with other components (e.g. tungsten), there is a consensus that cobalt is the main etiological agent for the development of hard metal lung disease [36, 187, 298, 308-310].

4.6. Skin

Occupational contact dermatitis (OCD) is the most common skin disease among all occupational skin diseases [46]. It is mainly caused by contact with metallic Co, Cr and Ni, since these metals are frequently encountered contact allergens in the workplace [1, 311]. Even short and repetitive contact with hard metals may cause harm, according to the findings of Midander et al. [312]. Athavale et al. [45] performed a retrospective analysis on an extended pool of dermatological data, collected over a period of 11 years. Occupational contact dermatitis was found to comprise 77% of all types of occupational skin diseases, with Cr and Co as etiological allergen in 6% and 4% of the cases, respectively. Furthermore, Co-related OCD seems to have an onset early in the work life and may affect a wide range of occupations [45]. The hands involve the greatest risk of cobalt sensitization, for obvious reasons [1, 45, 313-316]. However, Sarma [48] assessed the allergic profile among Indian construction workers and observed that dermatitis

not only affected the exposed body parts (94%), but also the covered parts (62%). Among construction workers, chromate is the most common allergen (60%) followed by Co and Ni (20%), all of which are present in cement. Isolated allergy to Co and Ni without concomitant chromate allergy is highly unlikely in this population, because Co and Ni are present in their insoluble form and therefore have a very low sensitization potential [317]. Consequently, Co and Ni allergies generally occur secondary to an existing chromate allergy that already caused skin damage, which was confirmed by the findings of Sarma [48]. Moreover, Co allergy often coexists with Ni allergy due to their common presence in metal objects. Fischer et al. [313] even concluded that sensitization to Ni may increase the risk of developing Co allergy.

Furthermore, skin effects in the environmental setting seem to be mainly caused by jewelry, cosmetic products and leather. For jewelry and cosmetics, only a few cases of skin problems have been described in literature. Chave et al. [318] reported a case of severe hand eczema in a beauty therapist after using a Co-containing gel for facial massage. The eczema disappeared when she avoided the product. Guarneri et al. [319] described a case of extremely itchy and eczematous lesions on the hands of a woman who undergone a nail-art procedure with Co-containing nail gel. Furthermore, a 45-year-old woman who bought a necklace in Spain developed eczema in the neck. A strong Co release was detected from the necklace using the artificial sweat method [93]. The presence of Co in leather was brought to light by a case report of a patient with chronic allergic contact dermatitis [109]. The patient linked his skin problems to his leather couch, which was later found to contain Co. Moreover, he tested positive for Co but not for Cr on patch testing. This finding led to a more extensive study, in which 183 dermatitis patients who tested positive for Co and not for Cr were identified. A questionnaire revealed that leather was found to be the most likely source of their problems [110].

Finally, dermatological reactions have been associated with (oral) Co therapy. The symptoms mainly consisted of acne, skin rashes and flares of dermatitis, which were temporary and mild in most cases [283, 284, 320, 321].

4.7. Psychological function

The following psychological problems have been reported among patients with MoM hip implants [238, 241]: depression, irritability, extreme fatigue and lack of energy, and anxiety. However, a direct cause-and-effect relationship with Co is uncertain, since this is an extremely versatile problem with a lot of possible underlying factors.

4.8. Carcinogenic effect

The risk of lung cancer related to inhalation of Co-containing dusts has been considered in the occupational exposure setting. However, Co is certainly not the main causative agent in this context; especially the combination with tungsten carbide is considered carcinogenic [5, 322]. The International Agency for Research on Cancer (IARC) classified the mixture Co/WC as 'probably carcinogenic to humans' (group 2A) [5].

Furthermore, there have been some concerns regarding an increased risk for cancer in patients with MoM implants. Numerous epidemiology studies were conducted to evaluate the total and specific cancer rates in implanted patients, but none revealed any indication of an increased cancer risk [323-336].

5. Conclusions

This review aimed to provide a general overview of all historical and contemporary cobalt sources, which were allocated to four categories of exposure. Furthermore, the detection and quantification methods of Co intake were illustrated and recent perspectives on the interpretation of these measures were given. Lastly, the known systemic health effects were described.

In the *occupational* setting, Co exposure is considered to be most prevalent in the hard metal industry, with a wide range of systemic Co levels (urine/blood). This might partially result from the variability in working conditions and protective measures taken in the workplace. *Environmental* Co exposure is extremely versatile and place-dependent, and therefore difficult to quantify in general. Risks for eco- and human toxicity have been estimated, but mainly based on measurements of the Co content and release from these sources, as there is a current lack of physiological biomarker (blood/urine) levels to accurately characterize the amount of human exposure. Moreover, Co often coincides with other metals in environmental sources, and the cumulative toxicity may be hazardous for human health. *Dietary intake* is considered to be the primary exposure route for the general population. Except for vitamin B_{12} and other Co supplements, cobalt is found in ubiquitous nutrients. The background Co levels (blood) are based on a normal dietary Co exposure, which is believed to include no risks for human health. *Medical* exposure to Co is a growing concern, especially in patients implanted with a metal-on-metal hip prosthesis, who are subjected to the most invasive Co exposure route. However, recent human volunteer studies demonstrated that ingestion of over-the-counter Co supplements can lead to considerably higher systemic Co levels than those measured in most MoM hip implant patients [25].

The systemic health effects of excessive cobalt exposure are characterized by a complex clinical syndrome with a varying set of neurological, cardiovascular and endocrine deficits, directly related to the uptake of Co ions in the tissues and blood circulation. However, the often wide range of systemic Co levels in symptomatic patients suggests that other factors might also influence the clinical image. This hampered the establishment of a 'threshold Co concentration' above which toxic effects are known to arise and therapeutic measures should be taken. A recently developed biokinetic model [26, 227] has clarified several issues regarding the dose-response characteristics of Co-related adverse health effects, showing that blood Co concentrations under 300 µg/l (100 µg/l respecting a safety factor of 3, to account for inter-individual variability and long-term Co exposure) are unlikely to result in clinically relevant symptoms for healthy individuals. Furthermore, chronic exposure to acceptable doses (see Unice et al. [26] and Tvermoes et al. [25]) are not expected to pose significant health hazards. Nevertheless, several cases presenting with systemic health effects at much lower doses (mostly from 20 µg/l) have been described in clinical practice, which may be explained by an increased susceptibility of the individual for Co-induced toxicity. This is assumed to originate from a shift towards a higher fraction of free Co^{2+} ions compared to albumin-bound Co in the serum, which may be caused by several underlying disease states that can affect the albumin or reduce the Co^{2+}-binding capacity in human blood. Therefore, monitoring the free Co^{2+} concentration might be more helpful than the total blood Co concentration for risk assessment in the future [2]. In addition, further clinical and longitudinal research is required within the population of MoM hip implant patients to elucidate the current dose-response controversies and contribute to the development of uniform guidelines.

Acknowledgements

Not applicable.

Funding

Laura Leyssens is funded by a PhD grant of the University of Ghent (Belgium). The authors have sole responsibility for the writing and content of the paper, and the views expressed are those of the authors and do not reflect those of the institutes mentioned on the title page.

6. References

1. Barceloux DG. Cobalt. J Toxicol Clin Toxicol. 1999;37(2):201-206.
2. Paustenbach DJ, Tvermoes BE, Unice KM, et al. A review of the health hazards posed by cobalt. Crit Rev Toxicol. 2013;43(4):316-362.
3. Strachan S. Trace elements. Curr Anaesth Crit Care. 2010;21(1):44-48.
4. Agency for Toxicological Substances and Disease Registry (ATSDR). Toxicological profile for cobalt. U.S. Department of Health and Human Services, Public Health Service. 2004.
5. International Agency for Research on Cancer (IARC), Working Group on the Evaluation of Carcinogenic Risk to Humans. Cobalt in hard metals and cobalt sulfate, gallium arsenide, indium phosphide and vanadium pentoxide. 2006.
6. Campbell JR, Estey MP. Metal release from hip prostheses: cobalt and chromium toxicity and the role of the clinical laboratory. Clin Chem Lab Med. 2013;51(1):213-220.
7. Borowska S, Brzóska MM. Metals in cosmetics: Implications for human health. J Appl Toxicol. 2015;35(6):551-572.
8. Delaunay C, Petit I, Learmonth ID, et al. Metal-on-metal bearings total hip arthroplasty: the cobalt and chromium ions release concern. Orthop Traumatol Surg Res. 2010;96(8):894-904.
9. Devlin JJ, Pomerleau AC, Brent J, et al. Clinical features, testing, and management of patients with suspected prosthetic hip-associated cobalt toxicity: a systematic review of cases. J Med Toxicol. 2013;9(4):405-415.
10. Nordberg G. Assessment of risks in occupational cobalt exposures. Sci Total Environ. 1994;150(1-3):201-207.
11. Pizon AF, Abesamis M, King AM, et al. Prosthetic hip-associated cobalt toxicity. J Med Toxicol. 2013;9(4):416-417.
12. Bocca B, Pino A, Alimonti A, et al. Toxic metals contained in cosmetics: a status report. Regul Toxicol Pharmacol. 2014;68(3):447-467.
13. Bradberry SM, Wilkinson JM, Ferner RE. Systemic toxicity related to metal hip prostheses. Clin Toxicol (Phila). 2014;52(8):837-847.
14. Christensen JM, Poulsen OM. A 1982–1992 surveillance programme on Danish pottery painters. Biological levels and health effects following exposure to soluble or insoluble cobalt compounds in cobalt blue dyes. Sci Total Environ. 1994;150(1-3):95-104.
15. Gessner BD, Steck T, Woelber E, et al. A Systematic Review of Systemic Cobaltism After Wear or Corrosion of Chrome-Cobalt Hip Implants. J Patient Saf. 2015. doi:10.1097/pts.0000000000000220.

16. Zywiel M, Cherian J, Banerjee S, et al. Systemic cobalt toxicity from total hip arthroplasties review of a rare condition Part 2. measurement, risk factors, and step-wise approach to treatment. Bone Joint J. 2016;98(1):14-20.

17. Catalani S, Rizzetti MC, Padovani A, et al. Neurotoxicity of cobalt. Hum Exp Toxicol. 2012;31(5):421-437.

18. De Boeck M, Kirsch-Volders M, Lison D. Cobalt and antimony: genotoxicity and carcinogenicity. Mutat Res. 2003;533(1-2):135-152.

19. Beyersmann D, Hartwig A. The genetic toxicology of cobalt. Toxicol Appl Pharmacol. 1992;115(1):137-145.

20. Fowler JFJ. Cobalt. Dermatitis. 2016;27(1):3-8.

21. Garner LA. Contact dermatitis to metals. Dermatol Ther. 2004;17(4):321-327.

22. Jarvis JQ, Hammond E, Meier R, et al. Cobalt cardiomyopathy: A report of two cases from mineral assay laboratories and a review of the literature. J Occup Med. 1992;34(6):620-626.

23. Rizzetti MC, Liberini P, Agosti C, et al. Cobalt neurotoxicity: A lesson from hip arthroplasty. J Neurol. 2009;256:S94.

24. Finley BL, Unice KM, Kerger BD, et al. 31-day study of cobalt (II) chloride ingestion in humans: pharmacokinetics and clinical effects. J Toxicol Environ Health A. 2013;76(21):1210-1224.

25. Tvermoes BE, Paustenbach DJ, Kerger BD, et al. Review of cobalt toxicokinetics following oral dosing: Implications for health risk assessments and metal-on-metal hip implant patients. Crit Rev Toxicol. 2015;45(5):367-387.

26. Unice KM, Kerger BD, Paustenbach DJ, et al. Refined biokinetic model for humans exposed to cobalt dietary supplements and other sources of systemic cobalt exposure. Chem Biol Interact. 2014;216(1):53-74.

27. International Agency for Research on Cancer (IARC). Chlorinated drinking-water; chlorination by-products; some other halogenated compounds; cobalt and cobalt compounds. 1991.

28. Klasson M, Bryngelsson L, Pettersson C, et al. Occupational Exposure to Cobalt and Tungsten in the Swedish Hard Metal Industry: Air Concentrations of Particle Mass, Number, and Surface Area. Ann Occup Hyg. 2016;60(6):684-699.

29. Lison D, Lauwerys R, Demedts M, et al. Experimental research into the pathogenesis of cobalt/hard metal lung disease. Eur Respir J. 1996;9(5):1024-1028.

30. Lison D, Lauwerys R. Study of the mechanism responsible for the elective toxicity of tungsten carbide-cobalt powder toward macrophages. Toxicol Lett. 1992;60(2):203-210.

31. Broding HC, Michalke B, Goeen T, et al. Comparison between exhaled breath condensate analysis as a marker for cobalt and tungsten exposure and biomonitoring in workers of a hard metal alloy processing plant. Int Arch Occup Environ Health. 2009;82(5):565-573.

32. Scansetti G, Botta GC, Spinelli P, et al. Absorption and excretion of cobalt in the hard metal industry. Sci Total Environ. 1994;150(1-3):141-144.

33. Hutter H-P, Wallner P, Moshammer H, et al. Dust and Cobalt Levels in the Austrian Tungsten Industry: Workplace and Human Biomonitoring Data. Int J Environ Res Public Health. 2016;13(9):931.

34. Kusaka Y, Yokoyama K, Sera Y, et al. Respiratory diseases in hard metal workers: an occupational hygiene study in a factory. Br J Ind Med. 1986;43(7):474-485.

35. Kumagai S, Kusaka Y, Goto S. Cobalt exposure level and variability in the hard metal industry of Japan. Am Ind Hyg Assoc J. 1996;57(4):365-369.

36. Kraus T, Schramel P, Schaller KH, et al. Exposure assessment in the hard metal manufacturing industry with special regard to tungsten and its compounds. Occup Environ Med. 2001;58(10):631-634.

37. Stefaniak AB, Virji MA, Day GA. Characterization of exposures among cemented tungsten carbide workers. Part I: Size-fractionated exposures to airborne cobalt and tungsten particles. J Expos Sci Environ Epidemiol. 2008;19(5):475-491.

38. Simonsen LO, Harbak H, Bennekou P. Cobalt metabolism and toxicology - a brief update. Sci Total Environ. 2012;432:210-215.

39. Peters S, Vermeulen R, Portengen L, et al. SYN-JEM: A Quantitative Job-Exposure Matrix for Five Lung Carcinogens. Ann Occup Hyg. 2016;60(7):795-811.

40. Coble JB, Lees PS, Matanoski G. Time trends in exposure measurements from OSHA compliance inspections of the pulp and paper industry. Appl Occup Environ Hyg. 2001;16(2):263-270.

41. Kauppinen T, Uuksulainen S, Saalo A, et al. Trends of occupational exposure to chemical agents in Finland in 1950–2020. Ann Occup Hyg. 2012;57(5):593-609.

42. Koh D-H, Nam J-M, Graubard BI, et al. Evaluating temporal trends from occupational lead exposure data reported in the published literature using meta-regression. Ann Occup Hyg. 2014;58(9):1111-1125.

43. Wang B-J, Wu J-D, Sheu S-C, et al. Occupational hand dermatitis among cement workers in Taiwan. J Formos Med Assoc. 2011;110(12):775-779.

44. Morrone A, Bordignon V, Barnabas GA, et al. Clinical-epidemiological features of contact dermatitis in rural and urban communities in northern Ethiopia: correlation with environmental or occupational exposure. Int J Dermatol. 2014;53(8):975-980.

45. Athavale P, Shum KW, Chen Y, et al. Occupational dermatitis related to chromium and cobalt: experience of dermatologists (EPIDERM) and occupational physicians (OPRA) in the U.K. over an 11-year period (1993-2004). Br J Dermatol. 2007;157(3):518-522.

46. Uter W, Ruhl R, Pfahlberg A, et al. Contact allergy in construction workers: results of a multifactorial analysis. Ann Occup Hyg. 2004;48(1):21-27.

47. Condé-Salazar L, Guimaraens D, Villegas C, et al. Occupational allergic contact dermatitis in construction workers. Contact Dermatitis. 1995;33(4):226-230.

48. Sarma N. Occupational allergic contact dermatitis among construction workers in India. Indian J Dermatol. 2009;54(2):137-141.

49. Kang DH, Chen M, Ogunseitan OA. Potential environmental and human health impacts of rechargeable lithium batteries in electronic waste. Environ Sci Technol. 2013;47(10):5495-5503.

50. Nnorom IC, Osibanjo O. Heavy metal characterization of waste portable rechargeable batteries used in mobile phones. Int J Environ Sci Technol (Tehran). 2009;6(4):641-650.

51. Lim SR, Schoenung JM. Human health and ecological toxicity potentials due to heavy metal content in waste electronic devices with flat panel displays. J Hazard Mater. 2010;177(1-3):251-259.

52. Grant K, Goldizen FC, Sly PD, et al. Health consequences of exposure to e-waste: a systematic review. Lancet Glob Health. 2013;1(6):350-361.

53. Fujimori T, Takigami H, Agusa T, et al. Impact of metals in surface matrices from formal and informal electronic-waste recycling around Metro Manila, the Philippines, and intra-Asian comparison. J Hazard Mater. 2012;221-222:139-146.

54. Sthiannopkao S, Wong MH. Handling e-waste in developed and developing countries: Initiatives, practices, and consequences. Sci Total Environ. 2013;463:1147-1153.

55. Julander A, Lundgren L, Skare L, et al. Formal recycling of e-waste leads to increased exposure to toxic metals: an occupational exposure study from Sweden. Environ Int. 2014;73:243-251.

56. Caravanos J, Clark E, Fuller R, et al. Assessing Worker and Environmental Chemical Exposure Risks at an e-Waste Recycling and Disposal Site in Accra, Ghana. Journal of Health and Pollution. 2011;1(1):16-25.

57. Demedts M, Gheysens B, Nagels J, et al. Cobalt lung in diamond polishers. Am Rev Respir Dis. 1984;130(1):130-135.

58. Gheysens B, Auwerx J, Van den Eeckhout A, et al. Cobalt-induced bronchial asthma in diamond polishers. Chest. 1985;88(5):740-744.

59. Nemery B, Casier P, Roosels D, et al. Survey of cobalt exposure and respiratory health in diamond polishers. Am Rev Respir Dis. 1992;145(3):610-616.

60. Nemery B, Nagels J, Verbeken E, et al. Rapidly fatal progression of cobalt lung in a diamond polisher. Am Rev Respir Dis. 1990;141(5 Pt 1):1373-1378.

61. van den Oever R, Roosels D, Douwen M, et al. Exposure of diamond polishers to cobalt. Ann Occup Hyg. 1990;34(6):609-614.

62. Krakowiak A, Dudek W, Tarkowski M, et al. Occupational asthma caused by cobalt chloride in a diamond polisher after cessation of occupational exposure: a case report. Int J Occup Med Environ Health. 2005;18(2):151-158.

63. Van Cutsem E, Ceuppens J, Lacquet L, et al. Combined asthma and alveolitis induced by cobalt in a diamond polisher. Eur J Respir Dis. 1987;70(1):54-61.

64. Jensen AA, Tuchsen F. Cobalt exposure and cancer risk. Crit Rev Toxicol. 1990;20(6):427-437.

65. Prescott E, Netterstrom B, Faber J, et al. Effect of occupational exposure to cobalt blue dyes on the thyroid volume and function of female plate painters. Scand J Work Environ Health. 1992;18(2):101-104.

66. Pirilä V. On Occupational Diseases of the Skin among Paint Factory Workers, Painters, Polishers and Varnishers in Finland. A Clinical and Experimental Study. Acta Derm Venereol. 1947;27(Suppl 16):163.

67. Kanerva L, Jolanki R, Estlander T. Offset printer's occupational allergic contact dermatitis caused by cobalt-2-ethylhexoate. Contact Dermatitis. 1996;34(1):67-68.

68. Tabor EC, Warren VW. Distribution of certain metals in the atmosphere of some American cities. Arch Environ Health. 1958;17:CONF-570402-.

69. Hamilton E. The geobiochemistry of cobalt. Sci Total Environ. 1994;150(1):7-39.

70. Smith H, Carson B. Trace metals in the environment. Volume 6: cobalt. An appraisal of environmental exposure. Ann Arbor, MI: Ann Arbor Science. 1981.

71. Rahn KA. Sources of trace elements in aerosols: an approach to clean air. Michigan University. Ann Arbor. Department of Metereology and Oceanography. 1971.

72. Salmon L, Atkins DHF, Fisher EMR, et al. Retrospective trend analysis of the content of U.K. air particulate material 1957-1974. Sci Total Environ. 1978;9(2):161-199.

73. Schroeder HA, Nason AP, Tipton IH. Essential trace metals in man: cobalt. J Chronic Dis. 1967;20(11):869-890.

74. Agency for Toxicological Substances and Disease Registry (ATSDR). ATSDR's Toxicological Profiles. Cobalt. U.S. Public Health Service. 1997.

75. Punsar S, Erämetsä O, Karvonen MJ, et al. Coronary heart disease and drinking water: a search in two Finnish male cohorts for epidemiologic evidence of a water factor. J Chronic Dis. 1975;28(5):259-287.

76. Expert Group on Vitamins and Minerals, UK Food Standards Agency. Review of Cobalt. 2002.

77. Feng S, Wang X, Wei G, et al. Leachates of municipal solid waste incineration bottom ash from Macao: heavy metal concentrations and genotoxicity. Chemosphere. 2007;67(6):1133-1137.

78. Abanades S, Flamant G, Gagnepain B, et al. Fate of heavy metals during municipal solid waste incineration. Waste Manag Res. 2002;20(1):55-68.

79. Gray JE, Eppinger RG. Distribution of Cu, Co, As, and Fe in mine waste, sediment, soil, and water in and around mineral deposits and mines of the Idaho Cobalt Belt, USA. Appl Geochem. 2012;27(6):1053-1062.

80. Cheyns K, Banza LNC, Ngombe LK, et al. Pathways of human exposure to cobalt in Katanga, a mining area of the D.R. Congo. Sci Tot Environ. 2014;490:313-321.

81. Banza CLN, Asosa J, Kabamba LN, et al., editors. Sources of exposure to cobalt and other metals in populations from Likasi and Lake Changalele in Katanga, D.R. Congo. In: Mining and the environment in Africa Proceedings. 2011, Kitwe/Zambia. Czech Geological Survey.

82. De Putter T, Decrée S, Banza CLN, et al., editors. Mining the Katanga (DRC) Copperbelt: geological aspects and impacts on public health and the environment – towards a holistic approach. In: Mining and the environment in Africa Proceedings. 2011, Kitwe/Zambia. Czech Geological Survey.

83. Kabamba LN, Asosa J, Mutombo A, et al., editors. High exposure to cobalt and other metals in mineworkers and malachite workers in Katanga, D.R. Congo. In: Mining and the environment in Africa Proceedings. 2011, Kitwe/Zambia. Czech Geological Survey.

84. Banza CLN, Nawrot TS, Haufroid V, et al. High human exposure to cobalt and other metals in Katanga, a mining area of the Democratic Republic of Congo. Environ Res. 2009;109(6):745-752.

85. Kluger N, Raison-Peyron N, Guillot B. [Contact dermatitis to nickel related to cellular phone use]. Presse Med. 2009;38(11):1694-1696.

86. Lee DY, Yang JM. Preauricular eczema: a sign of cellular phone dermatitis. Clin Exp Dermatol. 2010;35(2):201-202.

87. Aquino M, Mucci T, Chong M, et al. Mobile phones: Potential sources of nickel and cobalt exposure for metal allergic patients. Pediatr Allergy Immunol Pulmonol. 2013;26(4):181-186.

88. European Union (EU). Council Directive 76/768/EEC of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products. 1976;L 262:169.

89. European Union (EU). Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. 2009;L 342:59.

90. Basgel S, Erdemoglu SB. Determination of mineral and trace elements in some medicinal herbs and their infusions consumed in Turkey. Sci Total Environ. 2006;359(1-3):82-89.

91. Jallad KN, Espada-Jallad C. Spectroscopic characterization of geological materials from the United Arab Emirates. Arab J Geosci. 2008;1(2):119-127.

92. Gasser U, Klier B, Kuhn AV, et al. Current findings on the heavy metal content in herbal drugs. Pharmeur Sci Notes. 2009;2009(1):37-50.

93. Hindsen M, Persson L, Gruvberger B. Allergic contact dermatitis from cobalt in jewellery. Contact Dermatitis. 2005;53(6):350-351.

94. Thyssen JP, Linneberg A, Menne T, et al. The epidemiology of contact allergy in the general population--prevalence and main findings. Contact Dermatitis. 2007;57(5):287-299.

95. Thyssen JP, Jellesen MS, Menne T, et al. Cobalt release from inexpensive jewellery: has the use of cobalt replaced nickel following regulatory intervention? Contact Dermatitis. 2010;63(2):70-76.

96. Hamann D, Hamann C, Li LF, et al. The sino-american belt study: Nickel and cobalt exposure, epidemiology, and clinical considerations. Dermatitis. 2012;23(3):117-123.

97. Boonchai W, Maneeprasopchoke P, Suiwongsa B, et al. Assessment of nickel and cobalt release from jewelry from a non-nickel directive country. Contact Dermatitis. 2015;26(1):44-48.

98. Hamann D, Thyssen JP, Hamann CR, et al. Jewellery: alloy composition and release of nickel, cobalt and lead assessed with the EU synthetic sweat method. Contact Dermatitis. 2015;73(4):231-238.

99. Hamann C, Hamann D, Hamann KK, et al. Cobalt release from inexpensive earrings from Thailand and China. Contact Dermatitis. 2011;64(4):238-240.

100. Larese F, Maina G, Adami G, et al. In vitro percutaneous absorption of cobalt. Int Arch Occup Environ Health. 2004;77(2):85-89.

101. Filon FL, D'Agostin F, Crosera M, et al. In vitro absorption of metal powders through intact and damaged human skin. Toxicol In Vitro. 2009;23(4):574-579.

102. Raj S, Jose S, Sumod US, et al. Nanotechnology in cosmetics: Opportunities and challenges. J Pharm Bioallied Sci. 2012;4(3):186-193.

103. van Ketel WG, Liem DH. Eyelid dermatitis from nickel contaminated cosmetics. Contact Dermatitis. 1981;7(4):217.

104. Zemba C, Romaguera C, Vilaplana J. Allergic contact dermatitis from nickel in an eye pencil. Contact Dermatitis. 1992;27(2):116.

105. Saxena M, Warshaw E, Ahmed DD. Eyelid allergic contact dermatitis to black iron oxide. Am J Contact Dermat. 2001;12(1):38-39.

106. Larese F, Gianpietro A, Venier M, et al. In vitro percutaneous absorption of metal compounds. Toxicol Lett. 2007;170(1):49-56.

107. Travassos AR, Bruze M, Dahlin J, et al. Allergic contact dermatitis caused by nickel in a green eye pencil. Contact Dermatitis. 2011;65(5):307-308.

108. Rogero SO, Higa OZ, Saiki M, et al. Cytotoxicity due to corrosion of ear piercing studs. Toxicol In Vitro. 2000;14(6):497-504.

109. Thyssen JP, Johansen JD, Jellesen MS, et al. Consumer leather exposure: an unrecognized cause of cobalt sensitization. Contact Dermatitis. 2013;69(5):276-279.

110. Bregnbak D, Thyssen JP, Zachariae C, et al. Association between cobalt allergy and dermatitis caused by leather articles–a questionnaire study. Contact Dermatitis. 2015;72(2):106-114.

111. Bjoernber A. Allergic reaction to cobalt in light blue tattoo markings. Acta Derm Venereol. 1961;41(4):259.

112. World Health Organization (WHO). Cobalt and Inorganic Cobalt Compounds. In: Kim JH, Gibb HJ, Howe PD, ed. Concise International Chemical Assessment Document 69. Geneva: WHO; 2006:1-84.

113. Stuckert J, Nedorost S. Low-cobalt diet for dyshidrotic eczema patients. Contact Dermatitis. 2008;59(6):361-365.

114. Hokin B, Adams M, Ashton J, et al. Comparison of the dietary cobalt intake in three different Australian diets. Asia Pac J Clin Nutr. 2004;13(3):289-291.

115. Biego G, Joyeux M, Hartemann P, et al. Daily intake of essential minerals and metallic micropollutants from foods in France. Sci Total Environ. 1998;217(1):27-36.

116. Arnich N, Sirot V, Riviere G, et al. Dietary exposure to trace elements and health risk assessment in the 2nd French Total Diet Study. Food Chem Toxicol. 2012;50(7):2432-2449.

117. Gal J, Hursthouse A, Tatner P, et al. Cobalt and secondary poisoning in the terrestrial food chain: data review and research gaps to support risk assessment. Environ Int. 2008;34(6):821-838.

118. Health Canada. Canadian Total Diet Study. Dietary Intakes of Contaminants and Other Chemicals for Different Age–Sex Groups of Canadians. Vancouver; 2007. http://www.hc-sc.gc.ca/fn-an/surveill/total-diet/intake-apport/chem_age-sex_chim_2007-eng.php#cont. Accessed December 12, 2016.

119. Health Canada. Canadian Total Diet Study. Dietary Intakes of Contaminants and Other Chemicals for Different Age–Sex Groups of Canadians. Montreal; 2003. http://www.hc-sc.gc.ca/fn-an/surveill/total-diet/intake-apport/chem_age-sex_chim_2003-eng.php. Accessed December 12, 2016.

120. Health Canada. Canadian Total Diet Study. Dietary Intakes of Contaminants and Other Chemicals for Different Age–Sex Groups of Canadians. Toronto; 2005. http://www.hc-sc.gc.ca/fn-an/surveill/total-diet/intake-apport/chem_age-sex_chim_2005-eng.php. Accessed December 12, 2016.

121. Health Canada. Canadian Total Diet Study. Dietary Intakes of Contaminants and Other Chemicals for Different Age–Sex Groups of Canadians. Halifax; 2006. http://www.hc-sc.gc.ca/fn-an/surveill/total-diet/intake-apport/chem_age-sex_chim_2006-eng.php. Accessed December 12, 2016.

122. Nasreddine L, Hwalla N, El Samad O, et al. Dietary exposure to lead, cadmium, mercury and radionuclides of an adult urban population in Lebanon: a total diet study approach. Food Addit Contam. 2006;23(6):579-590.

123. Turconi G, Minoia C, Ronchi A, et al. Dietary exposure estimates of twenty-one trace elements from a Total Diet Study carried out in Pavia, Northern Italy. Br J Nutr. 2009;101(8):1200-1208.

124. Rose M, Baxter M, Brereton N, et al. Dietary exposure to metals and other elements in the 2006 UK Total Diet Study and some trends over the last 30 years. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2010;27(10):1380-1404.

125. Domingo JL, Perello G, Gine Bordonaba J. Dietary intake of metals by the population of Tarragona County (Catalonia, Spain): results from a duplicate diet study. Biol Trace Elem Res. 2012;146(3):420-425.

126. Discount Remedies Inc (DRI). Cobalt Supplement, Ionic Mineral Supplement, 96 Day Supply - 8 oz. In: Mineralife: product description and supplement facts. 2011. http://www.discountremediesinc.com/ionic-mineral-cobalt-supplement-8-oz.html. Accessed December 14, 2016.

127. Desert Rain Nutrition (DRN). Liquid Ionic Angstrom Cobalt. 2012. http://www.desertrainnutrition.com/index.php?main_page=product_info&cPath=2011_2018&productp_id=2192. Accessed December 14, 2016.

128. Mother Earth Minerals Inc (MEMI). Cobalt 2 oz. 2011. http://www.meminerals.com/catalog/cobalt-2-oz/. Accessed December 14 2016.

129. Institute of Medicine (IOM). Dietary reference intakes for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline.Washington DC: National Academy Press; 2000.

130. Lippi G, Franchini M, Guidi GC. Blood doping by cobalt. Should we measure cobalt in athletes? J Occup Med Toxicol. 2006;1(1):18.

131. Jelkmann W, Lundby C. Blood doping and its detection. Blood. 2011;118(9):2395-2404.

132. Higgins JP, Tuttle TD, Higgins CL. Energy Beverages: Content and Safety. Mayo Clinic Proceedings. 2010;85(11):1033-1041.

133. Christensen JM, Poulsen OM, Thomsen M. A short-term cross-over study on oral administration of soluble and insoluble cobalt compounds: sex differences in biological levels. Int Arch Occup Environ Health. 1993;65(4):233-240.

134. Elinder CG, Friberg L. Cobalt. In: Friberg L, Nordberg G, Vouk VB, ed. Handbook on the toxicology of metals. New York: Elsevier Science Pub; 1986:211-232.

135. Harp M, Scoular FI. Cobalt metabolism of young college women on self selected diets. J Nutr. 1952;47:67-72.

136. Moshtaghie A, Badii A, Mohammadian T. The comparative study of binding characteristics of cobalt and iron to human serum transferrin. J Res Med Sci. 2004;9(6):250-254.

137. Smith T, Edmonds C, Barnaby C. Absorption and retention of cobalt in man by whole-body counting. Health Phys. 1972;22(4):359-367.

138. Sorbie J, Olatunbosun D, Corbett WE, et al. Cobalt excretion test for the assessment of body iron stores. CMAJ. 1971;104(9):777.

139. Valberg LS, Ludwig J, Olatunbosun D. Alteration in cobalt absorption in patients with disorders of iron metabolism. Gastroenterology. 1969;56:241-251.

140. Reuber S, Kreuzer M, Kirchgessner M. Interactions of cobalt and iron in absorption and retention. J Trace Elem Electrolytes Health Dis. 1994;8(3-4):151-158.

141. Lison D. Speciation of Cobalt. In: Handbook of Elemental Spciation II – Species in the Environment, Food, Medicine and Occupational Health. Cornelis R, Caruso J, Crews H, et al., editors. John Wiley & Sons, Ltd; 2005. p. 158-173.

142. Collecchi P, Esposito M, Brera S, et al. The distribution of arsenic and cobalt in patients with laryngeal carcinoma. J Appl Toxicol. 1986;6(4):287-289.

143. Forbes R, Cooper A, Mitchell H. On the occurrence of beryllium, boron, cobalt, and mercury in human tissues. J Biol Chem. 1954;209:857-865.

144. Hewitt P. Accumulation of metals in the tissues of occupationally exposed workers. Environ Geochem Health. 1988;10(3-4):113-116.

145. Ishihara N, Koizumi M, Yoshida A. Metal concentrations in human pancreatic juice. Int Arch Environ Health. 1987;42(6):356-360.

146. Muramatsu Y, Parr R. Concentrations of some trace elements in hair, liver and kidney from autopsy subjects - relationship between hair and internal organs. Sci Total Environ. 1988;76(1):29-40.

147. Teraoka H. Distribution of 24 elements in the internal organs of normal males and the metallic workers in Japan. Int Arch Environ Health. 1981;36(4):155-165.

148. Yamagata N, Murata S, Torii T. The cobalt content of human body. J Radiat Res. 1962;3(1):4-8.

149. Yukawa M, Suzuki-Yasumoto M, Amano K, et al. Distribution of trace elements in the human body determined by neutron activation analysis. Int Arch Environ Health. 1980;35(1):36-44.

150. Gardner FH. The use of cobaltous chloride in the anemia associated with chronic renal disease. J Lab Clin Med. 1953;41(1):56-64.

151. Rohn R, Bond W, Klotz L. The effect of cobalt-iron therapy in iron deficiency anemia in infants. J Indiana State Med Assoc. 1953;46(12):1253.

152. Wolf J, Levy IJ. Treatment of sickle-cell anemia with cobalt chloride. AMA Arch Intern Med. 1954;93(3):387-396.

153. Taylor A, Marks V, Shabaan A, et al., ed. Cobalt-induced lipaemia and erythropoiesis. Clinical chemistry and chemical toxicology of metals: Proceedings of the First International Symposium; 1977.

154. Domingo JL. Cobalt in the environment and its toxicological implications. Rev Environ Contam Toxicol. 1989;108:105-132.

155. Wright JV. Bio-Identical Steroid Hormone Replacement: Selected Observations from 23 Years of Clinical and Laboratory Practice. Ann N Y Acad Sci. 2005;1057(1):506-524.

156. Bozic KJ, Kurtz S, Lau E, et al. The epidemiology of bearing surface usage in total hip arthroplasty in the United States. J Bone Joint Surg Am. 2009;91(7):1614-1620.

157. Kwon Y-M, Lombardi AV, Jacobs JJ, et al. Risk stratification algorithm for management of patients with metal-on-metal hip arthroplasty. J Bone Joint Surg Am. 2014;96(1):e4.

158. Corten K, MacDonald SJ. Hip resurfacing data from national joint registries: what do they tell us? What do they not tell us? Clin Orthop Relat Res. 2010;468(2):351-357.

159. Jiang Y, Zhang K, Die J, et al. A systematic review of modern metal-on-metal total hip resurfacing vs standard total hip arthroplasty in active young patients. J Arthroplasty. 2011;26(3):419-426.

160. American Society for Testing and Materials (ASTM). Standard Specification for Cobalt-28Chromium-6Molybdenum Alloy Forgings for Surgical Implants (UNS R31537, R31538, R31539). ASTM F799-11. West Conshohocken, PA; 2011.

161. American Society for Testing and Materials (ASTM). Standard Specification for Wrought Cobalt-28 Chromium-6 Molybdenum Alloys for Surgical Implant (UNS R31537, UNS R331538, and UNS R31539). ASTM F1537-11. West Conshohocken, PA; 2011.

162. American Society for Testing and Materials (ASTM). Standard Specification for Cobalt-28 Chromium-6 Molybdenum Alloy Castings and Casting Alloy for Surgical Implants (UNS R30075). ASTM F75-12. West Conshohocken, PA; 2012.

163. Lie SA, Engesæter LB, Havelin LI, et al. Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty Register. Acta Orthop Scand. 2000;71(1):19-27.

164. Sampson B, Hart A. Clinical usefulness of blood metal measurements to assess the failure of metal-on-metal hip implants. Ann Clin Biochem. 2012;49(Pt 2):118-131.

165. De Smet K, Cambell P, Van Der Straten C. Introduction. In: De Smet K, Campbell P, Van Der Straeten C, ed. The hip resurfacing handbook. A practical guide to the use and management of modern hip resurfacings. Oxford, Cambridge, Philadelphia, New Delhi: Woodhead Publishing Limited; 2013:27-31.

166. Doorn PF, Campbell PA, Worrall J, et al. Metal wear particle characterization from metal on metal total hip replacements: transmission electron microscopy study of periprosthetic tissues and isolated particles. J Biomed Mater Res. 1998;42(1):103-111.

167. Mabilleau G, Kwon Y-M, Pandit H, et al. Metal-on-metal hip resurfacing arthroplasty: a review of periprosthetic biological reactions. Acta Orthop. 2008;79(6):734-747.

168. Kwon Y-M, Xia Z, Glyn-Jones S, et al. Dose-dependent cytotoxicity of clinically relevant cobalt nanoparticles and ions on macrophages in vitro. Biomed Mater. 2009;4(2):025018.

169. Hart AJ, Sandison A, Quinn P, et al. Microfocus study of metal distribution and speciation in tissue extracted from revised metal on metal hip implants. In: Ser JPC, ed. 14th International Conference on X-Ray Absorption Fine Structure (XAFS14): IOP Publishing Ltd; 2009.

170. Kop AM, Swarts E. Corrosion of a hip stem with a modular neck taper junction: a retrieval study of 16 cases. J Arthroplasty. 2009;24(7):1019-1023.

171. Hart AJ, Quinn PD, Sampson B, et al. The chemical form of metallic debris in tissues surrounding metal-on-metal hips with unexplained failure. Acta Biomater. 2010;6(11):4439-4446.

172. Hart A, Buddhdev P, Winship P, et al. Cup inclination angle of greater than 50 degrees increases whole blood concentrations of cobalt and chromium ions after metal-on-metal hip resurfacing. Hip Int. 2008;18(3):212-219.

173. Langton D, Jameson S, Joyce T, et al. The effect of component size and orientation on the concentrations of metal ions after resurfacing arthroplasty of the hip. J Bone Joint Surg Br. 2008;90(9):1143-1151.

174. Bolland B, Culliford D, Langton D, et al. High failure rates with a large-diameter hybrid metal-on-metal total hip replacement. Clinical, radiological and retrieval analysis. J Bone Joint Surg Br. 2011;93(5):608-615.

175. Vendittoli P-A, Amzica T, Roy AG, et al. Metal Ion Release With Large-Diameter Metal-on-Metal Hip Arthroplasty. J Arthroplasty. 2011;26(2):282-288.

176. Huber M, Reinisch G, Trettenhahn G, et al. Presence of corrosion products and hypersensitivity-associated reactions in periprosthetic tissue after aseptic loosening of total hip replacements with metal bearing surfaces. Acta Biomater. 2009;5(1):172-180.

177. Catelas I, Medley JB, Campbell PA, et al. Comparison of in vitro with in vivo characteristics of wear particles from metal–metal hip implants. J Biomed Mater Res B Appl Biomater. 2004;70(2):167-178.

178. Goode AE, Perkins JM, Sandison A, et al. Chemical speciation of nanoparticles surrounding metal-on-metal hips. Chem Commun. 2012;48(67):8335-8337.

179. Pourzal R, Catelas I, Theissmann R, et al. Characterization of wear particles generated from CoCrMo alloy under sliding wear conditions. Wear. 2011;271(9):1658-1666.

180. Jacobs JJ, Skipor AK, Patteson LM, et al. Metal release in patients who have has a primary total hip arthroplasty - A prospective, controlled, longitudinal study. J Bone Joint Surg Am. 1998;80A(10):1447-1458.

181. Shahgaldi B, Heatley F, Dewar A, et al. In vivo corrosion of cobalt-chromium and titanium wear particles. J Bone Joint Surg Br. 1995;77(6):962-966.

182. Madl AK, Liong M, Kovochich M, et al. Toxicology of wear particles of cobalt-chromium alloy metal-on-metal hip implants Part I: physicochemical properties in patient and simulator studies. Nanomedicine. 2015;11(5):1201-1215.

183. Lewis A, Heard P. The effects of calcium phosphate deposition upon corrosion of CoCr alloys and the potential for implant failure. J Biomed Mater Res A. 2005;75(2):365-373.

184. Lewis A, Kilburn M, Papageorgiou I, et al. Effect of synovial fluid, phosphate-buffered saline solution, and water on the dissolution and corrosion properties of CoCrMo alloys as used in orthopedic implants. J Biomed Mater Res A. 2005;73(4):456-467.

185. Paustenbach DJ, Galbraith DA, Finley BL. Interpreting cobalt blood concentrations in hip implant patients. Clin Toxicol (Phila). 2014;52(2):98-112.

186. Wahlberg JE. Patch testing. In: Rycroft RJG, Menne, T., Frosch, P.J., et al., ed. Textbook of Contact Dermatitis. 3rd ed. Berlin: Springer; 2001:435–464.

187. Goldoni M, Catalani S, De Palma G, et al. Exhaled breath condensate as a suitable matrix to assess lung dose and effects in workers exposed to cobalt and tungsten. Environ Health Perspect. 2004;112(13):1293-1298.

188. Mutti A, Corradi M. Recent developments in human biomonitoring: non-invasive assessment of target tissue dose and effects of pneumotoxic metals. Med Lav. 2006;97(2):199-206.

189. Apostoli P, Porru S, Alessio L. Cobalt and Hard Metal Disease Urinary cobalt excretion in short time occupational exposure to cobalt powders. Sci Total Environ. 1994;150(1):129-132.

190. American Conference of Governmental Industrial Hygienists (ACGIH). TLVs and BEIs: threshold limit values for chemical and physical agents and biological exposure indices. Cincinnati, U.S.; 2010.

191. Van Der Straeten C. The genesis and aftermath of metal ions and particles in metal-on-metal hip arthroplasty [dissertation]. Ghent, Belgium: Ghent University; 2013.

192. Smolders JM, Bisseling P, Hol A, et al. Metal ion interpretation in resurfacing versus conventional hip arthroplasty and in whole blood versus serum. How should we interpret metal ion data. Hip Int. 2011;21(5):587-595.

193. Newton AW, Ranganath L, Armstrong C, et al. Differential distribution of cobalt, chromium, and nickel between whole blood, plasma and urine in patients after metal-on-metal (MoM) hip arthroplasty. J Orthop Res. 2012;30(10):1640-1646.

194. Paustenbach DJ, Tvermoes BE, Otani JM, et al., ed. Abstract Number 2556/Poster Board-144. Cobalt blood concentrations and health effects in adult volunteers during a 90-day cobalt supplement ingestion study. Society of Toxicology's (SOT) 52nd Annual Meeting; 2013: Society of Toxicology.

195. Daniel J, Ziaee H, Pynsent P, et al. The validity of serum levels as a surrogate measure of systemic exposure to metal ions in hip replacement. Bone Joint J. 2007;89(6):736-741.

196. MacDonald SJ. Can a safe level for metal ions in patients with metal-on-metal total hip arthroplasties be determined? J Arthroplasty. 2004;19(8):71-77.

197. De Haan R, Pattyn C, Gill H, et al. Correlation between inclination of the acetabular component and metal ion levels in metal-on-metal hip resurfacing replacement. Bone Joint J. 2008;90(10):1291-1297.

198. Heisel C, Streich N, Krachler M, et al. Characterization of the running-in period in total hip resurfacing arthroplasty: an in vivo and in vitro metal ion analysis. J Bone Joint Surg Am. 2008;90(Suppl 3):125-133.

199. Haddad F, Thakrar R, Hart A, et al. Metal-on-metal bearings: the evidence so far. Bone Joint J. 2011;93(5):572-579.

200. Langton D, Jameson S, Joyce T, et al. Accelerating failure rate of the ASR total hip replacement. J Bone Joint Surg Br. 2011;93(8):1011-1016.

201. Medicines and Healthcare products Regulatory Agency (MHRA). Medical device alert of the Medicines and Healthcare products Regulatory Agency on all metal-on-metal (MoM) hip replacements (MDA/2010/033). 2010.

202. Langton DJ, Jameson SS, Joyce TJ, et al. Early failure of metal-on-metal bearings in hip resurfacing and large-diameter total hip replacement. A consequence of excess wear. J Bone Joint Surg Br. 2010;92B(1):38-46.

203. Cooper HJ, Della Valle CJ, Berger RA, et al. Corrosion at the head-neck taper as a cause for adverse local tissue reactions after total hip arthroplasty. J Bone Joint Surg Am. 2012;94(18):1655-1661.

204. Sidaginamale RP, Joyce TJ, Lord JK, et al. Blood metal ion testing is an effective screening tool to identify poorly performing metal-on-metal bearing surfaces. Bone Joint Res. 2013;2(5):84.

205. Sunderman FW, Hopfer SM, Swift T, et al. Cobalt, chromium, and nickel concentrations in body fluids of patients with porous-coated knee or hip prostheses. J Orthop Res. 1989;7(3):307-315.

206. Van Der Straeten C, Van Quickenborne D, Pennynck S, et al. Systemic toxicity of metal ions in a metal-on-metal hip arthroplasty population. Bone Joint J. 2013;95(Suppl 34):187.

207. Lardanchet J-F, Taviaux J, Arnalsteen D, et al. One-year prospective comparative study of three large-diameter metal-on-metal total hip prostheses: serum metal ion levels and clinical outcomes. Orthop Traumatol Surg Res. 2012;98(3):265-274.

208. Jacobs JJ, Skipor AK, Doorn PF, et al. Cobalt and chromium concentrations in patients with metal on metal total hip replacements. Clin Orthop Relat Res. 1996;329:S256-S263.

209. Clarke MT, Lee PTH, Arora A, et al. Levels of metal ions after small- and large- diameter metal-on-metal hip arthroplasty. J Bone Joint Surg Br. 2003;85(6):913-917.

210. Back DL, Young D, Shimmin A. How do serum cobalt and chromium levels change after metal-on-metal hip resurfacing? Clin Orthop Relat Res. 2005;438:177-181.

211. Vendittoli P-A, Mottard S, Roy A, et al. Chromium and cobalt ion release following the Durom high carbon content, forged metal-on-metal surface replacement of the hip. J Bone Joint Surg Br. 2007;89(4):441-448.

212. Antoniou J, Zukor DJ, Mwale F, et al. Metal ion levels in the blood of patients after hip resurfacing: a comparison between twenty-eight and thirty-six-millimeter-head metal-on-metal prostheses. J Bone Joint Surg Am. 2008;90:142-148.

213. De Smet K, De Haan R, Calistri A, et al. Metal ion measurement as a diagnostic tool to identify problems with metal-on-metal hip resurfacing. J Bone Joint Surg Am. 2008;90(Suppl 4):202-208.

214. Walter LR, Marel E, Harbury R, et al. Distribution of chromium and cobalt ions in various blood fractions after resurfacing hip arthroplasty. J Arthroplasty. 2008;23(6):814-821.

215. Engh CA, MacDonald SJ, Sritulanondha S, et al. 2008 John Charnley award: metal ion levels after metal-on-metal total hip arthroplasty: a randomized trial. Clin Orthop Relat Res. 2009;467(1):101-111.

216. Malek I, King A, Sharma H, et al. The sensitivity, specificity and predictive values of raised plasma metal ion levels in the diagnosis of adverse reaction to metal debris in symptomatic patients with a metal-on-metal arthroplasty of the hip. J Bone Joint Surg Br. 2012;94(8):1045-1050.

217. Van Der Straeten C, Grammatopoulos G, Gill HS, et al. The 2012 Otto Aufranc Award: The interpretation of metal ion levels in unilateral and bilateral hip resurfacing. Clin Orthop Relat Res. 2013;471(2):377-385.

218. Mayo Clinic. Test Catalog. Test ID: COS (80084) Cobalt, Serum. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/80084. Accessed December 17, 2016.

219. United States Food and Drug Administration (USFDA). Recalls Specific to Metal-on-Metal Hip Implants. Silver Spring, MD, U.S.; 2013.

220. Lombardi JAV, Barrack RL, Berend KR, et al. The Hip Society. Bone Joint Surg Br. 2012;94-B(11 Suppl A):14.

221. United Kingdom Medicines and Healthcare Products Regulatory Agency (UK MHRA). Medical device alert: metal-on-metal (MoM) total hip replacements (MDA/2012/016). 2012.

222. Finley BL, Monnot AD, Gaffney SH, et al. Dose-response relationships for blood cobalt concentrations and health effects: a review of the literature and application of a biokinetic model. J Toxicol Environ Health B Crit Rev. 2012;15(8):493-523.

223. Oldenburg M, Wegner R, Baur X. Severe Cobalt Intoxication Due to Prosthesis Wear in Repeated Total Hip Arthroplasty. J Arthroplasty. 2009;24(5):825.e815-825.e820.

224. Finley BL, Monnot AD, Paustenbach DJ, et al. Derivation of a chronic oral reference dose for cobalt. Regul Toxicol Pharmaco. 2012;64(3):491-503.

225. Tvermoes BE, Finley BL, Unice KM, et al. Cobalt whole blood concentrations in healthy adult male volunteers following two-weeks of ingesting a cobalt supplement. Food Chem Toxicol. 2013;53:432-439.

226. Tvermoes BE, Unice KM, Paustenbach DJ, et al. Effects and blood concentrations of cobalt after ingestion of 1 mg/d by human volunteers for 90 d. Am J Clin Nutr. 2014;99(3):632-646.

227. Unice KM, Monnot AD, Gaffney SH, et al. Inorganic cobalt supplementation: Prediction of cobalt levels in whole blood and urine using a biokinetic model. Food Chem Toxicol. 2012;50(7):2456-2461.

228. Brodner W, Bitzan P, Meisinger V, et al. Serum cobalt levels after metal-on-metal total hip arthroplasty. J Bone Joint Surg Am. 2003;85(11):2168-2173.

229. Alimonti A, Bocca B, Mannella E, et al. Assessment of reference values for selected elements in a healthy urban population. Ann Ist Super Sanita. 2005;41(2):181-187.

230. Hodnett D, Wood DM, Raja K, et al. A healthy volunteer study to investigate trace element contamination of blood samples by stainless steel venepuncture needles. Clin Toxicol (Phila). 2012;50(2):99-107.

231. Kerger BD, Gerads R, Gurleyuk H, et al. Cobalt speciation assay for human serum, Part I. Method for measuring large and small molecular cobalt and protein-binding capacity using size exclusion chromatography with inductively coupled plasma-mass spectroscopy detection. Toxicological & Environmental Chemistry. 2013;95(4):687-708.

232. Kerger BD, Tvermoes BE, Unice KM, et al. Cobalt speciation assay for human serum, Part II. Method validation in a study of human volunteers ingesting cobalt (II) chloride dietary supplement for 90 days. Toxicol Environ Chem. 2013;95(4):709-718.

233. Nandedkar AK, Basu PK, Friedberg F. Co++ binding by plasma proteins. Bioinorg Chem. 1973;2(2):149-157.

234. Merritt K, Brown S, Sharkey N. The binding of metal salts and corrosion products to cells and proteins in vitro. J Biomed Mater Res. 1984;18(9):1005-1015.

235. Caicedo MS, Pennekamp PH, McAllister K, et al. Soluble ions more than particulate cobalt-alloy implant debris induce monocyte costimulatory molecule expression and release of proinflammatory cytokines critical to metal-induced lymphocyte reactivity. J Biomed Mater Res A. 2010;93(4):1312-1321.

236. Keegan GM, Learmonth ID, Case CP. A systematic comparison of the actual, potential, and theoretical health effects of cobalt and chromium exposures from industry and surgical implants. Crit Rev Toxicol. 2008;38(8):645-674.

237. Lison D, Lauwerys R. Cobalt bioavailability from hard metal particles. Further evidence that cobalt alone is not responsible for the toxicity of hard metal particles. Arch Toxicol. 1994;68(8):528-531.

238. Tower S. Arthroprosthetic cobaltism: neurological and cardiac manifestations in two patients with metal-on-metal arthroplasty: a case report. J Bone Joint Surg Am. 2010;92(17):2847-2851.

239. Tower S. Arthroprosthetic cobaltism: identification of the at-risk patient. Alaska Med. 2010;52:28-32.

240. Cheung A, Banerjee S, Cherian J, et al. Systemic cobalt toxicity from total hip arthroplasties review of a rare condition Part 1-history, mechanism, measurements, and pathophysiology. Bone Joint J. 2016;98(1):6-13.

241. Mao X, Wong AA, Crawford RW. Cobalt toxicity--an emerging clinical problem in patients with metal-on-metal hip prostheses? Med J Aust. 2011;194(12):649-651.

242. Machado C, Appelbe A, Wood R. Arthroprosthetic cobaltism and cardiomyopathy. Heart Lung Circ. 2012;21(11):759-760.

243. Morin Y, Daniel P. Quebec beer-drinkers' cardiomyopathy: etiological considerations. CMAJ. 1967;97(15):926-928.

244. Milon H, Morin Y, Bonenfant J. [Epidemic of myocardosis in beer drinkers. Probable role of cobalt]. Arch Mal Coeur Vaiss. 1968;61(11):1561.

245. Bonenfant JL, Auger C, Miller G, et al. Québec beer-drinkers' myocardosis: pathological aspects. Ann N Y Acad Sci. 1969;156(1):577-582.

246. Dölle W. [Cobalt induced heart disease in chronic beer drinkers]. Internist (Berl). 1969;10(1):29-30.

247. Kesteloot H, Roelandt J, Willems J, et al. An enquiry into the role of cobalt in the heart disease of chronic beer drinkers. Circulation. 1968;37(5):854-864.

248. Barborik M, Dusek J. Cardiomyopathy accompaning industrial cobalt exposure. Br Heart J. 1972;34(1):113-116.

249. Kennedy A, Dornan JD, King R. Fatal myocardial disease associated with industrial exposure to cobalt. Lancet. 1981;317(8217):412-414.

250. Vermel AE, Nikitina LS, Barabanov AA, et al. [Cobalt-induced cardiomyopathy in workers engaged in the manufacture of hard alloys]. Ter Arkh. 1991;63(4):101-104.

251. Pelclova D, Sklensky M, Janicek P, et al. Severe cobalt intoxication following hip replacement revision: clinical features and outcome. Clin Toxicol (Phila). 2012;50(4):262-265.

252. Apel W, Stark D, Stark A, et al. Cobalt–chromium toxic retinopathy case study. Doc Ophthalmol. 2013;126(1):69-78.

253. Gilbert CJ, Cheung A, Butany J, et al. Hip pain and heart failure: the missing link. Can J Cardiol. 2013;29(5):639.e631- 639.e632.

254. O'Connell E, Mead N, Fesniak H. Idiopathic Cardiomyopathy Following Metal-on-Metal Hip Arthroplasty: The New Face of" Beer Drinker's Cardiomyopathy". Eur J Cardiovasc Med. 2013;2(3):210-211.

255. Zywiel MG, Brandt JM, Overgaard CB, et al. Fatal cardiomyopathy after revision total hip replacement for fracture of a ceramic liner. Bone Joint J. 2013;95-B(1):31-37.

256. Dahms K, Sharkova Y, Heitland P, et al. Cobalt intoxication diagnosed with the help of Dr House. Lancet. 2014;383(9916):574.

257. Fox KA, Phillips TM, Yanta JH, et al. Fatal cobalt toxicity after total hip arthroplasty revision for fractured ceramic components. Clin Toxicol. 2016;54(9):874-877.

258. Vasukutty NL, Minhas TH. Systemic effects of cobalt toxicity after revision hip replacement can manifest in intermediate to long term follow-up. Hip Int. 2016;26(4):e31-34.

259. Charette RS, Neuwirth AL, Nelson CL. Arthroprosthetic cobaltism associated with cardiomyopathy. Arthroplasty Today. 2016.

260. Horowitz SF, Fischbein A, Matza D, et al. Evaluation of right and left ventricular function in hard metal workers. Br J Ind Med. 1988;45:742-746.

261. Linna A, Oksa P, Groundstroem K, et al. Exposure to cobalt in the production of cobalt and cobalt compounds and its effect on the heart. Occup Environ Med. 2004;61(11):877-885.

262. Alexandersson R, Atterhög J. Studies on effects of exposure to cobalt: VII. heart effects of exposure to cobalt in Swedish hard metal industry. Arbete och Hälsa. 1980;9:1-21.

263. Raffn E, Mikkelsen S, Altman DG, et al. Health effects due to occupational exposure to cobalt blue dye among plate painters in a porcelain factory in Denmark. Scand J Work Environ Health. 1988;14(6):378-384.

264. Hock A, Demmel U, Schicha H, et al. Trace element concentration in human brain. Activation analysis of cobalt, iron, rubidium, selenium, zinc, chromium, silver, cesium, antimony and scandium. Brain. 1975;98(1):49-64.

265. Duckett S. Abnormal deposits of chromium in the pathological human brain. J Neurol Neurosurg Psychiatry. 1986;49(3):296-301.

266. Meecham H, Humphrey P. Industrial exposure to cobalt causing optic atrophy and nerve deafness: a case report. J Neurol Neurosurg Psychiatry. 1991;54(4):374.

267. Botelho CT, Paz APML, Gonçalves AM, et al. Comparative study of audiometrics tests on metallurgical workers exposed to noise only as well as noise associated to the handling of chemical products. Braz J Otorhinolaryngol. 2009;75(1):51-57.

268. Ikeda T, Takahashi K, Kabata T, et al. Polyneuropathy caused by cobalt-chromium metallosis after total hip replacement. Muscle Nerve. 2010;42(1):140-143.

269. Pazzaglia U, Apostoli P, Congiu T, et al. Cobalt, chromium and molybdenum ions kinetics in the human body: data gained from a total hip replacement with massive third body wear of the head and neuropathy by cobalt intoxication. Arch Orthop Trauma Surg. 2011;131(9):1299-1308.

270. Mohan M, Kasprowicz M, editors. Identification and Management of Cobalt Toxicity: A Case Report of Rapidly Progressing Toxicity after Hip Arthroplasty Revision. The Medicine Forum. 2016;17:18.

271. Steens W, Von Foerster G, Katzer A. Severe cobalt poisoning with loss of sight after ceramic-metal pairing in a hip - A case report. Acta Orthop. 2006;77(5):830-832.

272. Ng SK, Ebneter A, Gilhotra JS. Hip-implant related chorio-retinal cobalt toxicity. Indian J Ophthalmol. 2013;61(1):35-37.

273. Jordan C, Whitman RD, Harbut M, et al. Memory deficits in workers suffering from hard metal disease. Toxicol Lett. 1990;54(2):241-243.

274. Roy PE, Bonenfant JL, Turcot L. Thyroid changes in cases of Quebec beer drinkers myocardosis. Am J Clin Pathol. 1968;50(2):234-239.

275. Gross RT, Kriss JP, Spaet TH. The hematopoietic and goitrogenic effects of cobaltous chloride in patients with sickle cell anemia. Pediatrics. 1955;15(3):284-371.

276. Jaimet CH, Thode HG. Thyroid function studies on children receiving cobalt therapy. JAMA. 1955;158(15):1353-1355.

277. Kriss JP, Carnes WH, Gross RT. Hypothyroidism and thyroid hyperplasia in patients treated with cobalt. JAMA. 1955;157(2):117-121.

278. Robey JS, Veazey PM, Crawford JD. Cobalt-induced myxedema: report of a case. N Engl J Med. 1956;255(20):955-957.

279. Roche M, Layrisse M. Effect of cobalt on thyroidal uptake of I131. J Clin Endocrinol Metab. 1956;16:831-833.

280. Little JA, Sunico R. Cobalt-induced goiter with cardiomegaly and congestive failure. J Pediatr. 1958;52(3):284-288.

281. Paley KR, Sobel ES, Yalow RS. Effect of oral and intravenous cobaltous chloride on thyroid function. J Clin Endocrinol Metab. 1958;18(8):850-859.

282. Chamberlain JL. Thyroid enlargement probably induced by cobalt: A rerport of 3 cases. J Pediatr. 1961;59(1):81-86.

283. Davis JE, Fields JP. Experimental production of polycythemia in humans by administration of cobalt chloride. Exp Biol Med. 1958;99(2):493-495.

284. Holly RG. Studies on iron and cobalt metabolism. JAMA. 1955;158(15):1349-1352.

285. Swennen B, Buchet JP, Stanescu D, et al. Epidemiological survey of workers exposed to cobalt oxides, cobalt salts, and cobalt metal. Br J Ind Med. 1993;50(9):835-842.

286. Lantin AC, Mallants A, Vermeulen J, et al. Absence of adverse effect on thyroid function and red blood cells in a population of workers exposed to cobalt compounds. Toxicol Lett. 2011;201(1):42-46.

287. Jobs H, Ballhausen C. Powder metallurgy as a source of dust from the medical and technical standpoint. Vertrauensartz krankenkasse. 1940;8:142-148.

288. Bech A, Kipling M, Heather J. Hard metal disease. Br J Ind Med. 1962;19(4):239-252.

289. Roto P. Asthma, symptoms of chronic bronchitis and ventilatory capacity among cobalt and zinc production workers. Scand J Work Environ Health. 1980:1-49.

290. Coates EO, Watson JH. Diffuse interstitial lung disease in tungsten carbide workers. Ann Intern Med. 1971;75(5):709-716.

291. Coates OE, Watson JH. Pathology of the lung in tungsten carbide workers using light and electron microscopy. J Occup Environ Med. 1973;15(3):280-286.

292. Cugell DW, Morgan WKC, Perkins DG, et al. The respiratory effects of cobalt. Arch Intern Med. 1990;150(1):177-183.

293. Ruokonen EL, Linnainmaa M, Seuri M, et al. A fatal case of hard-metal disease. Scand J Work Environ Health. 1996;22(1):62-65.

294. Bezerra PN, Vasconcelos AG, Cavalcante LL, et al. Hard metal lung disease in an oil industry worker. J Bras Pneumol. 2009;35(12):1254-1258.

295. Kaneko Y, Kikuchi N, Ishii Y, et al. Upper lobe-dominant pulmonary fibrosis showing deposits of hard metal component in the fibrotic lesions. Intern Med. 2010;49(19):2143-2145.

296. Moreira MAC, Cardoso ARO, Silva DGST, et al. Hard metal pneumoconiosis with spontaneous bilateral pneumothorax. J Bras Pneumol. 2010;36(1):148-151.

297. Cugell DW. Cobalt-Related Lung Diseases. Clin Pulm Med. 1998;5(3):158-164.

298. Gotway MB, Golden JA, Warnock M, et al. Hard metal interstitial lung disease: high-resolution computed tomography appearance. J Thorac Imaging. 2002;17(4):314-318.

299. Dunlop P, Muller NL, Wilson J, et al. Hard metal lung disease: high resolution CT and histologic correlation of the initial findings and demonstration of interval improvement. J Thorac Imaging. 2005;20(4):301-304.

300. Capitani EMd, Algranti E. Other pneumoconioses. J Bras Pneumol. 2006;32:S54-S59.

301. Enriquez LS, Mohammed T, Johnson GL, et al. Hard metal pneumoconiosis: a case of giant-cell interstitial pneumonitis in a machinist. Respir Care. 2007;52(2):196.

302. Reddy PA, Gorelick DF, Christianson CS. Giant cell interstitial pneumonia (GIP). Chest. 1970;58(4):319-325.

303. Choi JW, Lee KS, Chung MP, et al. Giant cell interstitial pneumonia: high-resolution CT and pathologic findings in four adult patients. AJR Am J Roentgenol. 2005;184(1):268-272.

304. Maier LA. Clinical approach to chronic beryllium disease and other nonpneumoconiotic interstitial lung diseases. J Thorac Imaging. 2002;17(4):273-284.

305. Wahbi Z, Arnold A, Taylor AN. Hard metal lung disease and pneumothorax. Respir Med. 1997;91(2):103-105.

306. Dai J, Huang M, Cao M, et al. Giant cell interstitial pneumonia: unusual lung disorder and an update. Chin Med J (Engl). 2014;127(15):2819-2823.

307. Ruediger HW. Hard metal particles and lung disease: Coincidence or causality? Respiration. 2000;67(2):137-138.

308. Chiappino G. Hard metal disease: clinical aspects. Sci Total Environ. 1994;150(1):65-68.

309. Finch GL, Hoover MD, Hahn FF, et al. Animal models of beryllium-induced lung disease. Environ Health Perspect. 1996;104 Suppl 5:973-979.

310. Lison D. Toxicity of cobalt-containing dusts. Toxicol Appl Pharmacol. 2000;168(2):173-174.

311. Wahlberg JE. Other metals. In: Kanerva L, Wahlberg JE, Elsner P, ed. Handbook of Occupational Dermatology. Berlin: Springer; 2000:551-555.

312. Midander K, Julander A, Skare L, et al. Cobalt skin dose resulting from short and repetitive contact with hard metals. Contact Dermatitis. 2014;70(6):361-368.

313. Fischer T, Rystedt I. Cobalt allergy in hard metal workers. Contact Dermatitis. 1983;9(2):115-121.

314. Basketter D, Briatico-Vangosa G, Kaestner W, et al. Nickel, cobalt and chromium in consumer products: a role in allergic contact dermatitis? Contact Dermatitis. 1993;28(1):15-25.

315. Cherry N, Meyer J, Adisesh A, et al. Surveillance of occupational skin disease: EPIDERM and OPRA. Br J Dermatol. 2000;142(6):1128-1134.

316. Mussani F, DeKoven JG. Unilateral hand allergic contact dermatitis due to occupational exposure. J Cutan Med Surg. 2014;18(4):283-286.

317. Fregert S, Gruvberger B. Solubility of cobalt in cement. Contact Dermatitis. 1978;4(1):14-18.

318. Chave TA, Warin AP. Allergic contact dermatitis from cobalt in a beauty product. Contact Dermatitis. 1999;41(4):236.

319. Guarneri F, Guarneri C, Cannavò S. Nail-art and cobalt allergy. Contact Dermatitis. 2010;62(5):320.

320. Sidell CM, Erickson JG, McCleary JE. Cobalt folliculitis. Calif Med. 1958;88(1):20.

321. Veien N, Hattel T, Justesen O, et al. Oral challenge with nickel and cobalt in patients with positive patch tests to nickel and/or cobalt. Acta Derm Venereol. 1986;67(4):321-325.

322. Wild P, Bourgkard E, Paris C. Lung cancer and exposure to metals: the epidemiological evidence. Methods Mol Biol. 2009;472:139-167.

323. Gillespie W, Frampton C, Henderson R, et al. The incidence of cancer following total hip replacement. J Bone Joint Surg Br. 1988;70(4):539-542.

324. Visuri T, Koskenvuo M. Cancer risk after McKee-Farrar total hip replacement. Orthopedics. 1991;14(2):137-142.

325. Mathiesen E, Ahlbom A, Bermann G, et al. Total hip replacement and cancer. A cohort study. J Bone Joint Surg Br. 1995;77(3):345-350.

326. Nyrén O, McLaughlin JK, Gridley G, et al. Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden. J Natl Cancer Inst. 1995;87(1):28-33.

327. Visuri T, Pukkala E, Paavolainen P, et al. Cancer risk after metal on metal and polyethylene on metal total hip arthroplasty. Clin Orthop Relat Res. 1996;329:S280-S289.

328. Visuri T, Pukkala E, Pulkkinen P, et al. Decreased cancer risk in patients who have been operated on with total hip and knee arthroplasty for primary osteoarthrosis: a meta-analysis of 6 Nordic cohorts with 73,000 patients. Acta Orthop Scand. 2003;74(3):351-360.

329. Visuri T, Pulkkinen P, Paavolainen P, et al. Cancer risk is not increased after conventional hip arthroplasty: A nationwide study from the Finnish Arthroplasty Register with follow-up of 24,636 patients for a mean of 13 years. Acta Orthop. 2010;81(1):77-81.

330. Visuri TI, Pukkala E, Pulkkinen P, et al. Cancer incidence and causes of death among total hip replacement patients: a review based on Nordic cohorts with a special emphasis on metal-on-metal bearings. Proc Inst Mech Eng H. 2006;220(2):399-407.

331. Olsen JH, McLaughlin JK, Nyrén O, et al. Hip and knee implantations among patients with osteoarthritis and risk of cancer: A record-linkage study from Denmark. Int J Cancer. 1999;81(5):719-722.

332. Paavolainen P, Pukkala E, Pulkkinen P, et al. Cancer incidence in Finnish hip replacement patients from 1980 to 1995: a nationwide cohort study involving 31,651 patients. J Arthroplasty. 1999;14(3):272-280.

333. Signorello LB, Ye W, Fryzek JP, et al. Nationwide study of cancer risk among hip replacement patients in Sweden. J Natl Cancer Inst. 2001;93(18):1405-1410.

334. Smith AJ, Dieppe P, Porter M, et al. Risk of cancer in first seven years after metal-on-metal hip replacement compared with other bearings and general population: linkage study between

the National Joint Registry of England and Wales and hospital episode statistics. BMJ. 2012;344:e2383.

335. Lalmohamed A, MacGregor AJ, de Vries F, et al. Patterns of risk of cancer in patients with metal-on-metal hip replacements versus other bearing surface types: a record linkage study between a prospective joint registry and general practice electronic health records in England. PloS one. 2013;8(7):e65891.

336. Christian WV, Oliver LD, Paustenbach DJ, et al. Toxicology-based cancer causation analysis of CoCr-containing hip implants: a quantitative assessment of genotoxicity and tumorigenicity studies. J Appl Toxicol. 2014;34(9):939-967.

337. Morgan LG. A study into the health and mortality of men exposed to cobalt and oxides. Occup Med. 1983;33(4):181-186.

338. Ichikawa Y, Kusaka Y, Goto S. Biological monitoring of cobalt exposure, based on cobalt concentrations in blood and urine. Int Arch Occup Environ Health. 1985;55(4);269-276.

339. Scansetti G, Maina G, Botta GC, et al. Exposure to cobalt and nickel in the hard-metal production industry. Int Arch Occup Environ Health. 1998;71(1):60-63.

340. Yokota K, Johyama Y, Kunitani Y, et al. Urinary elimination of nickel and cobalt in relation to airborne nickel and cobalt exposures in a battery plant. Int Arch Occup Environ Health. 2007;80(6):527-531.

341. De Palma G, Manini P, Sarnico M, et al. Biological monitoring of tungsten (and cobalt) in workers of a hard metal alloy industry. Int Arch Occup Environ Health. 2010;83(2):173-181.

Table 1: Overview of the systemic Co concentrations reported in different studies about occupational Co exposure.

Study	Occupational source	Number of samples	Whole blood	Urine	Expression of the results
Alexanderson et al. (1980) [262]	Hard metal production	unknown	10.5 µg/l	134 µg/l	mean
Morgan (1983)[337]	Processing cobalt oxide	unknown		340 µg/l	mean
Ichikawa et al. (1985)[338]	Production of hard metal tools	175	3.3–18.7 µg/l	10–235 µg/l	range
Lison et al. (1994)[237]	Hard metal production	132		18.2–32.4 µg/g creatinine	range
Scansetti et al. (1998)[339]	Hard metal production	45		22.28 µg/l	mean
Yokota et al. (2007)[340]	Battery plant	16		28.2 ± 34.0 (1.0–127.8) µg/l	arithmetic mean ± standard deviation (range)
Broding et al. (2009)[31]	Hard metal alloy industry	52		0.81 (0.00–1.46) µg/l	median (interquartile range)
De Palma et al. (2010)[341]	Hard metal alloy industry	36		5.27 (2.95) µg/l	geometric means (geometric standard deviations)
Julander et al. (2014)[55]	E-waste recycling (formal methods)	50 (whole blood) 52 (urine)	0.081 (0.050–0.67) µg/l	0.25 (0.12–1.3) µg/l	median (range)
Nemery et al. (1992)[59]	Diamond polishing	194		0.1 – 137 µg/l	range
Prescott et al. (1992)[65]	Porcelain painting	25		1.17 µg/mmol	mean
Goldoni et al. (2004)[187]	Hard metal alloy industry	23		1.7-366 µmol/mol creatinine	range
	Grinding of hard metal	10		7.2–49.2 µmol/mol creatinine	range
Kraus et al. (2001)[36]	Hard metal production	87		0.19 – 227.8 µg/g creatinine	range
Hutter et al. (2016)[33]	Hard metal production	1166		3.7 (1–159.7) µg/l	median (range)